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ABSTRACT 
The rise and spread of drug-resistant pathogens has created a critical need for the 
continued discovery and development of new antibacterial compounds. Bacterial toxin-antitoxin 
(TA) systems consist of a toxin capable of arresting cell growth and an antitoxin that binds to 
and inhibits the toxin under normal circumstances. Cellular stress causes a shift in the 
toxin/antitoxin ratio to favor the free toxin, which is released to act on its cellular target and 
arrest growth. TA systems therefore present potential targets for novel antibiotics, as a molecule 
with the capacity to artificially induce toxin activation could have an antibacterial effect. 
Described herein is the investigation of the Staphylococcus aureus YefM-YoeBSa1 and YefM-
YoeBSa2 TA systems as targets for this artificial activation strategy. Following establishment of 
the prevalence, conservation, and transcription of the yefM-yoeBSa1 and yefM-yoeBSa2 genes in 
clinical isolates of methicillin-resistant S. aureus, a peptide activator of the YefM-YoeBSa1 TA 
system was sought by screening phage-displayed peptide libraries against the YefMSa1 antitoxin. 
Additionally, a novel strategy was devised to express the YoeBSa1 toxin in an inactive, non-toxic 
form. Characterization of the activity of YoeBSa1 led to the design of a fluorogenic substrate that 
can be used to screen for activators of this toxin in a high-throughput manner. 
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CHAPTER 1 
TOXIN-ANTITOXIN SYSTEMS AS NOVEL ANTIBACTERIAL TARGETS 
 
1.1  THE ANTIBACTERIAL RESISTANCE CRISIS 
Beginning with the first clinical use of penicillin, the time period between 1940 and 1970 
saw the introduction of thirteen new classes of antibiotics into the clinic (Figure 1.1) (1). During 
this “golden age” of antibiotics, the discovery of new antibacterial agents outpaced the 
emergence of resistance to existing antibiotics (2). However, the golden age was followed by a 
“discovery gap” during which no novel antibacterial classes were introduced, while resistance to 
every known class of antibiotics in clinical use gradually emerged. Horizontal gene transfer 
enabled the rapid dissemination of resistance determinants, resulting in the rise of multidrug- and 
Figure 1.1 Antibacterial introduction, use, and resistance in the clinic. Dates when novel 
classes of antibiotics were originally introduced to the clinic are indicated with circles 
containing “I.” Bars span time periods during which resistance to each antibiotic class was not 
observed in the clinic. Dates when resistance to any member of a class of antibiotics was 
reported in the clinic are indicated with circles containing “R.” 
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pan-drug-resistant pathogens with little or no susceptibility to available antibiotics (3). These 
events coincided with the gradual retreat of the pharmaceutical industry from antibacterial 
research due to diminishing returns and increasing regulatory barriers (4). Despite a revival in 
antibacterial drug discovery and the introduction of four new classes of antibiotics since 2000, 
clinical resistance has already been observed for all except the pleuromutilins (5-8). There is a 
critical need for the continued discovery of new antibiotics. 
 
1.2  TOXIN-ANTITOXIN SYSTEMS 
Artificial activation of bacterial toxin-antitoxin (TA) systems has been proposed as a 
novel antibacterial strategy (9-12). TA systems are genetic modules found on chromosomes and 
plasmids in almost all free-living bacteria (13). They consist of a protein toxin and a protein or 
RNA antitoxin that prevents the activity of the toxin under normal circumstances (14-16). 
Plasmid-Borne TA Systems—TA systems were originally discovered on plasmids, where 
they function by a post-segregational killing mechanism to maintain a plasmid in a bacterial 
population (Figure 1.2A). In daughter cells that inherit the TA-containing plasmid during 
replication, both the antitoxin and the toxin continue to be produced, and the cell survives. 
However, if the plasmid is not inherited by the daughter cell, the antitoxin can no longer be 
replenished, and the toxin is unleashed to act on its cellular target and kill the cell (17). 
Chromosomally-Encoded TA Systems—TA systems were subsequently discovered on the 
chromosomes of many bacteria and archaea (13,18,19). The function of chromosomally-encoded 
TA systems is somewhat controversial, with at least thirteen proposed roles (16,20,21), including 
junk DNA, selfish genes (20), stabilization of mobile genetic elements (22,23), anti-addiction 
elements (24), gene regulation (25-27), growth control/stress response (28-32), persistence 
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(26,33,34), growth arrest (35), programmed cell death (36-38), phage defense (39,40), biofilm 
formation (41), virulence (42), and phenotypic bistability (43). However, it is generally accepted 
that cellular stress modulates transcription at the TA locus and stimulates degradation of the 
antitoxin. These events shift the toxin/antitoxin ratio to favor the free toxin, which then acts on 
its cellular target to inhibit cell growth until conditions become more favorable (Figure 1.2B) 
(44). Upon cessation of stress, the antitoxin is replenished, inactivating the toxin and allowing 
the cell to resume normal growth (35). In some cases, prolonged toxin activation has been found 
to lead to a “point of no return” from which growth resumption is no longer possible (36,45).  
 
 
TA systems have been classified into five types based on the mechanism by which the 
antitoxin inhibits the toxin (Figure 1.3). 
Figure 1.2 Activation of plasmid-borne and chromosomally encoded TA systems. A, 
Activation of plasmid-borne TA systems. Top, a bacterial cell that possesses a plasmid 
encoding a TA system produces both the toxin (T) and the antitoxin (A), which form a stable 
complex that prevents the toxin from acting on its cellular target. Bottom left, a daughter cell 
that inherits the plasmid survives because the antitoxin can be replenished to prevent toxin 
activation. Bottom right, a daughter cell that does not inherit the plasmid dies because the 
antitoxin is degraded and cannot be replenished, so the toxin is released to act on its target 
and kill the cell. B, Activation of chromosomally encoded TA systems. The toxin and 
antitoxin are co-expressed from the chromosomal TA locus to form a stable complex under 
normal conditions. Cellular stress (lightning bolts) modulates transcription of the TA locus 
and activates cellular proteases to degrade the labile antitoxin. The toxin/antitoxin ratio shifts 
to favor the free toxin, which can act on its cellular target, inducing immediate growth arrest 
and eventual cell death. 
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Type I TA Systems—In Type I TA systems, regulation is achieved by complementary 
base-pairing between the antitoxin RNA and the full-length TA mRNA, which targets the full-
length transcript for degradation or prevents translation of the toxin (Figure 1.3A). Most Type I 
toxins are small hydrophobic proteins and are believed to function by insertion into the cell 
membrane and destabilization of membrane potential, leading to a reduction in ATP synthesis; 
inhibition of replication, transcription, and translation; and ultimately cell death (46). 
Type II TA Systems—In Type II TA systems, both the toxin and the antitoxin are small 
proteins that form an innocuous complex under normal circumstances (Figure 1.3B). The 
activity of Type II toxins is controlled by transcriptional autoregulation and proteolysis (21,47). 
Transcription of Type II TA genes is usually regulated by binding of the antitoxin and the TA 
complex to the TA promoter, although exceptions to this rule exist (14). Generally, the antitoxin 
acts as the principal repressor and the toxin as the corepressor. This mechanism has been termed 
“conditional cooperativity,” as binding of the toxin enhances repression at low toxin/antitoxin 
ratios by stabilizing the TA-operator complex but induces transcription at high toxin/antitoxin 
ratios by destabilizing the TA-operator complex (48-50). The antitoxin gene frequently precedes, 
and either overlaps or is separated by a few bases from, the toxin gene. This helps to ensure that 
cellular antitoxin levels are in vast excess of those necessary to inhibit the toxin, thereby 
reducing the risk of unnecessary or accidental toxin activation (15). 
At the protein level, Type II antitoxins, which are usually flexible polypeptides, bind 
tightly to their cognate toxins and prevent them from interacting with their cellular targets (16). 
Generally, antitoxins are relatively labile and much more susceptible to proteolysis than toxins. 
As a result, the supply of antitoxin must be continually replenished in order to maintain cellular 
levels capable of inhibiting the toxin. Antitoxin turnover is mediated by the ATP-dependent 
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Figure 1.3 Classification of TA systems. A, Type I TA systems. The antitoxin RNA 
complementary base-pairs with the full-length TA mRNA to promote degradation by a 
cellular RNase or prevent toxin translation and thereby allow growth. Degradation of the 
antitoxin RNA allows the toxin to be expressed and act on its target, causing growth arrest. B, 
Type II TA systems. The antitoxin protein binds to and inhibits the toxin protein to allow 
growth. Proteolytic degradation of the antitoxin and modulation of transcription produce free 
toxin that can act on its target and induce growth arrest. C, Type III TA systems. The 
antitoxin RNA binds to and inhibits the toxin protein to allow growth. Phage infection is 
believed to trigger antitoxin degradation and modulate transcription to produce free toxin that 
can act on its target and induce growth arrest. D, Type IV TA systems. The antitoxin protein 
binds to and protects the target from the toxin to allow growth. Free toxin is produced by an 
unknown mechanism and acts on the target to induce growth arrest. E, Type V TA systems. 
The RNase antitoxin degrade toxin RNA to allow growth. Degradation of the antitoxin RNA 
is hypothesized to allow the toxin to be expressed, act on its target, and induce growth arrest. 
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proteases Lon and Clp. Activation of these proteases depletes the cellular pool of antitoxin, 
freeing the toxin to act on its cellular target and inhibit growth or induce death (21). The modes 
of Type II toxin activity are diverse and include inhibition of DNA replication, protein synthesis, 
and cell wall biosynthesis. Many Type II toxins are ribonucleases (RNases) that cleave RNA in 
the presence or absence of the ribosome (15). 
 Type III TA Systems—Only one Type III TA system, ToxIN, has been extensively 
characterized to date (51). The antitoxin toxI transcript consists of 5.5 repeats of 36 nucleotides. 
ToxN is a sequence-specific, ribosome-independent RNase that processes the toxI transcript into 
monomeric ToxI RNAs of 36 nucleotides and cleaves other transcripts in addition to toxI. ToxI 
monomers form pseudoknots that assemble into triangular heterohexameric complexes with 
ToxN monomers, resulting in inhibition of ToxN (Figure 1.3C) (52). Transcription of the ToxIN 
locus is negatively autoregulated, and activation of ToxN occurs in response to phage infection, 
suggesting that phage invasion triggers a shift in the relative levels of ToxI and ToxN in favor of 
free ToxN (40). A recent survey of the BLASTp database identified 125 putative Type III TA 
loci divided into 3 families (53). 
 Type IV TA Systems—The Type IV TA system YeeUV was very recently described (54). 
The protein toxin YeeV binds to and prevents polymerization of the critical cytoskeletal and cell 
division proteins MreB and FtsZ, while the antitoxin YeeU stabilizes polymers of MreB and 
FtsZ (Figure 1.3D). The mechanism by which YeeV is activated is currently unknown. This is a 
novel TA design in that the antitoxin does not interact directly with the toxin but rather 
counteracts it indirectly (55). However, classification of YeeUV as a TA system is questionable, 
as the mechanism of indirect antagonism is not consistent with canonical TA systems that are 
regulated by direct interaction of the toxin and antitoxin components (16). 
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 Type V TA Systems—The Type V TA system GhoST was also very recently discovered. 
In contrast to Type II TA antitoxins, the GhoS antitoxin is a stable protein that does not 
negatively autoregulate transcription of the ghoST operon (Figure 1.3E). The GhoT toxin is a 
small hydrophobic protein that causes membrane damage and lysis to produce cells with “ghost” 
morphology. GhoS is an RNase and specifically cleaves ghoT mRNA to prevent translation of 
GhoT. Degradation of ghoS mRNA by the Type II RNase toxin MqsR is hypothesized to allow 
expression of GhoT, leading to the formation of ghost cells. The ghoST operon is conserved in E. 
coli and Shigella spp. (56), and orthologues have also been identified in Serratia and Erwinia 
(16). It remains to be seen whether additional Type V TA systems will be discovered. 
 
1.3  STRATEGIES FOR ARTIFICIAL TOXIN ACTIVATION 
The growth inhibitory and lethal consequences of toxin activation have led to the 
proposal that artificial toxin activation could provide an effective antibacterial strategy (9-12). 
Type II TA systems present ideal candidates for investigating the tractability of this strategy 
because they are currently the most widespread and best understood class of TA systems. 
Additionally, the presence, conservation, and transcription of a number of Type II TA systems 
has been verified in clinical isolates of some of the most dangerous drug-resistant pathogens, 
including vancomycin resistant enterococci (57), methicillin-resistant Staphylococcus aureus 
(MRSA), Pseudomonas aeruginosa (58), and Streptococcus pneumoniae (59). 
 
1.3.1  Mechanisms for Artificial Toxin Activation 
Several mechanisms for artificial toxin activation have been proposed (12). Toxin 
activation could be indirectly achieved by modulating transcription of the TA genes to shift 
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expression levels in favor of the free toxin or by activating cellular proteases to accelerate 
degradation of the antitoxin and relieve inhibition of the toxin. Although both of these 
mechanisms mimic those used endogenously to regulate the activity of TA systems, they are also 
indirect and consequently may have unpredictable off-target effects. Toxin activation could be 
more directly achieved by preventing formation of the TA complex or disrupting the complex 
after it has formed (Figure 1.4). By acting on the TA proteins themselves, these strategies would 
enable accurate assessment of the antibacterial efficacy of artificial toxin activation. 
  
 
1.3.2  Disruption of the Toxin-Antitoxin Interaction 
The direct mechanisms of toxin activation depicted in Figure 1.4 require the discovery of 
a molecule capable of modulating the protein-protein interaction (PPI) between a toxin and an 
antitoxin. TA interactions are usually extensive, with affinities in the nM to pM range (60-63). 
Currently, the majority of approved and clinically used drugs target enzymes, cell surface 
receptors, nuclear receptors, ion channels, and transporters (64). Prior knowledge of the natural 
ligand or substrate of these targets is often used to direct the rational design of small, “druglike” 
molecules that bind in relatively small, deep pockets or grooves (64-66). The resulting protein-
small molecule interactions involve contact surfaces of ~300-1000 Å
2
 (67,68). In contrast, PPIs 
Figure 1.4 Direct mechanisms for artificial toxin activation. A small molecule or peptide, 
depicted as a purple chain, could directly activate a toxin by (A) disrupting the TA complex 
after it has formed or (B) preventing formation of the complex. 
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such as those in Type II TA systems are relatively large, flat, and featureless, with contact 
surfaces of ~1500-3000 Å
2
 (69,70). Although these characteristics of PPIs were previously 
thought to render them “undruggable,” the number of small molecule inhibitors of PPIs is 
increasing, and several have now entered pre-clinical and clinical trials (71,72). 
The ability of small molecules to successfully compete with much larger proteins to 
inhibit PPIs can be understood in light of “hotspots,” which are a small number of residues that 
contribute a large fraction of the free energy of binding in a PPI but comprise less than half of 
the contact surface (73,74). Hotspots have traditionally been identified experimentally using 
alanine-scanning mutagenesis (74-76), but a number of computational methods have recently 
been introduced to enable in silico hotspot prediction (77). These techniques may be used in 
tandem to discover and validate hotspots involved in TA interactions and to facilitate the rational 
design and screening of small molecules or peptides capable of achieving direct toxin activation. 
A crucial consideration in the design of screens for direct toxin activators is the chemical 
space encompassed by the screening library. Chemoinformatic analysis of known PPI inhibitors 
indicates that they tend to be larger and more topologically complex, with greater hydrophobic 
and aromatic content, than compounds that hit traditional drug targets such as enzymes and 
receptors (78,79). However, commercially available chemical libraries are biased toward 
structures that hit traditional drug targets (80). This suggests that failure to discover an inhibitor 
of a particular PPI, such as the TA interaction, in a chemical screen could result not from a lack 
of “druggability” but rather from a lack of suitable scaffolds in the screening collection. 
Fortunately, there have been a number of recent efforts to generate libraries that sample 
regions of chemical space characteristic of known PPI inhibitors. These efforts have included 
derivatization of natural product core scaffolds (81); construction of new core scaffolds using 
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diversity-oriented synthesis (82,83) and complexity-to-diversity approaches (84); creation of 
cyclic and stapled peptide and peptidomimetic libraries using natural and unnatural amino acids 
(85-90); synthesis of DNA-encoded chemical libraries (91); and computational fragment-based 
screening (92). Employment of these libraries and synthetic approaches in screens for toxin 
activators may allow for a much greater chance of success than utilization of libraries designed 
for traditional drug targets. 
Taken together, the availability of mutational and computational methods to predict 
hotspots and rationally design inhibitors of PPIs, the creation of screening collections and the 
development of screening strategies biased toward the identification of compounds that inhibit 
PPIs, and the successful identification and progression to clinical trials of PPI inhibitors suggest 
that the time is ripe for the identification of a direct toxin activator. 
 
1.3.3  Activation via Toxin Binding 
Theoretically, a direct toxin activator could bind either to the toxin or to the antitoxin to 
relieve inhibition of the toxin. The two primary considerations influencing the decision of which 
protein to target are structure and activity. Antitoxins are typically partially or completely 
disordered proteins and often become more ordered upon binding to their cognate toxins. In 
contrast, toxins are usually well-ordered in both the presence and absence of their cognate 
antitoxins (21). The majority of drugs target ordered proteins (93), which suggests that it may be 
easier to identify small molecules or peptides that are capable of binding to the toxin rather than 
the antitoxin to modulate the TA interaction. In general, binding of an antitoxin molecule to a 
toxin molecule prohibits the toxin from binding to and acting on its target. It is vital to ensure 
that potential toxin activators do not similarly inhibit the toxin’s ability to act on its target. An 
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example of toxin inhibition by potential toxin-binding activators is provided by a screen for the 
ability of peptide fragments from the Bacillus anthracis antitoxin PemI to prevent binding of 
PemI to the toxin PemK. Peptides with the greatest ability to inhibit formation of the PemIK 
complex also inhibited the RNase activity of PemK (94). Given that the peptides were derived 
from PemI, it is perhaps not surprising that some would inhibit PemK. Nonetheless, the 
discovery that peptides derived from an antitoxin can prevent formation of a TA complex is 
promising, as it suggests that the TA interaction can be modulated by small molecules. 
In some TA systems, binding of the antitoxin to the toxin induces a conformational 
change in the toxin that renders it catalytically inactive. The toxin-binding strategy may prove 
best-suited for these systems, as it may be possible to identify a molecule that is able to stabilize 
the toxin in a catalytically competent conformation that cannot be bound by the antitoxin, 
thereby allowing the toxin to remain active and possibly even enhancing its activity. An example 
of such an activity-enhancing activator is provided by the only successful toxin-binding toxin 
activator reported in the literature to date. The pentapeptide NNWNN, or “extracellular death 
factor” (EDF), was originally discovered as a quorum-sensing molecule that induced cell death 
in E. coli in response to brief antibiotic stress. Intriguingly, cell death was dependent on the 
presence of the mazEF Type II TA system (95). In vitro experiments subsequently revealed that 
EDF binds directly to the MazF toxin, significantly enhances the RNase activity of MazF, and 
prevents complex formation between MazF and the antitoxin MazE (96). Although independent 
attempts to replicate these results have been unsuccessful (14,97,98), the discovery of EDF is a 
promising indication that relatively short peptides and perhaps small molecules are capable of 
artificial toxin activation via toxin binding. 
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1.3.4  Activation via Antitoxin Binding 
Antitoxins belong to a growing class of intrinsically disordered proteins (IDPs) that 
partially or completely lack stable secondary and tertiary structure (99). IDPs have considerable 
therapeutic potential due to their essential roles in signaling and regulation and their involvement 
in cancer, neurodegenerative diseases, cardiovascular diseases, and diabetes (100). Although 
IDPs present challenging drug targets due to their lack of structure, a number of small molecules 
that are able to bind to IDPs and modulate their ability to interact with other proteins have been 
discovered (93,99,101-103). Importantly, the mechanisms by which these molecules bind to 
IDPs can be used to inform the search for toxin activators that bind to the antitoxin. 
At least three mechanisms are possible for inhibiting the ability of the antitoxin to interact 
with the toxin using a small molecule that binds to the antitoxin. First, a small molecule could 
bind to and induce or stabilize order in a small, ordinarily disordered portion of the antitoxin and 
thereby prevent the remainder of the antitoxin from interacting with, or properly folding upon 
binding to, the toxin. Alternatively, a small molecule could bind to and induce or stabilize a 
folded or misfolded conformation of the antitoxin that is incapable of interacting with the toxin. 
Finally, a small molecule could bind to the antitoxin and induce or stabilize monomeric or 
oligomeric forms that are unable to interact with the toxin. Although there have been no 
published efforts to target antitoxins to date, the multiplicity of mechanisms by which a small 
molecule could bind to an antitoxin to prevent it from interacting with a toxin, as well as the 
growing realization that IDPs are tractable drug targets, suggests that artificial toxin activation 
via a small molecule that binds to and sequesters the antitoxin could be a viable strategy. 
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1.4  TARGETING TOXIN-ANTITOXIN SYSTEMS IN STAPHYLOCOCCUS AUREUS  
Staphylococcus aureus is the leading cause of bloodstream, lower respiratory tract, and 
skin and soft tissue infections worldwide (104). Methicillin resistant S. aureus (MRSA) was first 
isolated in the clinic in 1960 (105). MRSA now accounts for over 60% of S. aureus infections in 
US hospitals (106) and is responsible for the deaths of approximately 16,000 hospitalized 
patients in the US annually (107). This statistic is roughly equivalent to the number of American 
deaths due to AIDS, tuberculosis, and viral hepatitis combined (108). Moreover, although the 
occurrence of methicillin-sensitive S. aureus (MSSA) infections remained roughly constant 
between 1998 and 2007, the number of MRSA infections increased by more than 60% (109). 
Vancomycin is currently the regimen of choice for MRSA (110), but increased incidence 
of treatment failure has been observed due to strains with reduced susceptibility or outright 
resistance acquired via mutation and horizontal gene transfer, respectively (111-115). Moreover, 
resistance to even the newest “drugs of last resort” for MRSA infections, linezolid and 
daptomycin, was reported within one and two years, respectively, of their introduction to the 
clinic (115,116). Due to its propensity to acquire resistance determinants, the emergence of pan-
drug-resistant S. aureus is inevitable. Thus there is an urgent need to develop new strategies to 
combat drug-resistant S. aureus infections. A recent metagenomic survey identified between one 
and seven TA systems in the sequenced genomes of fourteen S. aureus strains, including two 
homologues of the YefM-YoeB TA system (YefM-YoeBSa1 and YefM-YoeBSa2) (117). These 
systems present ideal targets for the investigation of artificial toxin activation as a novel 
antibacterial strategy against this dangerous pathogen. 
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1.4.1  YefM-YoeBEc 
The YefM-YoeB TA system was first discovered by homology of hypothetical proteins 
from Escherichia coli, Streptomyces coelicolor, Mycobacterium tuberculosis, and S. aureus with 
a predicted TA cassette found on the Francisella tularensis plasmid pFNL10 (118). The 
hypothetical proteins from E. coli, YefMEc and YoeBEc, were subsequently rediscovered in a 
search for homologues of the Axe-Txe TA system found on pRUM, a multidrug resistance 
plasmid from a clinical isolate of Enterococcus faecium. Expression of YoeBEc in the absence of 
YefMEc was found to significantly reduce cellular viability, indicating that YefM-YoeBEc was a 
bona-fide TA system in which YoeBEc was the toxin and YefMEc was the antitoxin (119). 
YefMEc was subsequently identified as a substrate for the ATP-dependent protease Lon. Lon-
mediated degradation of YefMEc resulted in activation of YoeBEc, inhibition of translation, and 
mRNA cleavage, suggesting that YoeBEc was an RNase and a translation inhibitor (120). 
The crystal structure of the YefM-YoeBEc complex supported this hypothesis (Figure 
1.5). In the crystal structure, the N-termini of two YefMEc monomers form a symmetrical dimer 
(121) that was later found to negatively autoregulate transcription of the yefM-yoeBEc genes 
(122). The C-terminus of one YefMEc monomer forms a bent alpha helix that cradles YoeBEc, 
while the C-terminus of the other monomer is disordered in the crystal structure. Geometric and 
steric considerations preclude binding of a second YoeBEc monomer to the complex. YoeBEc 
bears significant structural homology to the guanosine-specific RNases RNase Sa from 
Streptomyces aureofaciens and Barnase from Bacillus amyloliquefaciens. Although the putative 
active site residues are displaced from a catalytically competent orientation by binding of 
YefMEc, the catalytic Glu-Arg-His triad found in RNase Sa, Barnase, and other microbial 
guanosine-specific RNases is conserved in YoeBEc. YoeBEc exhibited ribosome-independent 
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RNase activity toward free mRNA transcripts in vitro, and this activity was inhibited by addition 
of YefMEc. The proposed catalytic residues were confirmed by site-directed mutagenesis, and 
primer extension analysis was used to determine that YoeBEc cleaves free mRNA after purine 
residues with a preference for adenosine over guanosine (121). 
However, independent attempts to observe ribosome-independent RNase activity of 
YoeBEc in vitro and in E. coli were unsuccessful (123,124). Instead, exhaustive investigation into 
the mechanism by which YoeBEc inhibits protein synthesis suggested that YoeBEc functions 
primarily as a ribosome-dependent RNase in vitro and in E. coli. YoeBEc was found to bind to 
the ribosomal A site and cleave mRNA transcripts three bases downstream of the start codon, 
resulting in inhibition of translation initiation, growth arrest, and eventual cell death (124). 
The YefM-YoeBEc TA system possesses many characteristics that may translate to the 
discovery of a YoeBEc activator with antibacterial activity. First, YoeBEc inhibits translation 
Figure 1.5 Crystal structure of the YefM-YoeBEc complex (PDB ID 2A6Q). YefMEc 
monomers are depicted in blue and cyan. YoeBEc is depicted in green, and the active site is 
indicated with an arrow. N- and C-termini are labeled “N” and “C,” respectively. The C-
terminus of the YefMEc monomer depicted in cyan is disordered and is not shown. 
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initiation and induces growth arrest (124), which suggests that a YoeBEc activator would have 
bacteriostatic activity and could therefore provide a useful antibiotic. Additionally, YoeBEc 
exhibits structural features that may facilitate the discovery of a toxin-binding activator. The 
observation that binding of YefMEc induces a conformational change in the active site of YoeBEc 
(121) suggests that a small molecule or peptide could bind to and stabilize an active 
conformation of YoeBEc that cannot be recognized by YefMEc. One potential limitation of an 
activator that binds to YoeBEc is that such a molecule could inhibit the ability of YoeBEc to bind 
to the ribosome. However, if the activator enhances the ribosome-independent RNase activity of 
YoeBEc, inhibition of binding to the ribosome may not be a concern. YefMEc also exhibits 
structural features that may facilitate the discovery of an antitoxin-binding activator. With the 
exception of the C-terminus of the YefMEc monomer that is not involved in binding to YoeBEc, 
the majority of the YefMEc dimer is well-folded (121). This suggests that it may be possible to 
identify a small molecule or peptide that binds to and sequesters the C-terminal region of YefMEc 
in a conformation that is unable to interact with YoeBEc. 
 
1.4.2  YefMMtb 
The crystal structure of YefMMtb from M. tuberculosis has also been solved (125), 
making YefM-YoeB one of the few TA systems for which the crystal structures of the antitoxin 
alone and in complex with the toxin are available. YefMMtb crystallized as a heterotetramer 
(Figure 1.6). The N-terminal portions of the YefMMtb monomers are nearly superimposable and 
resemble those of the YefMEc monomers in the crystal structure of YefM-YoeBEc (Figure 1.5). 
However, significant differences are observed for the distal C-terminal regions (residues 64-91). 
In two of the monomers, the C-terminal residues are partially or completely disordered and do 
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not interact, while in the other two monomers, the C-terminal residues fold into helices and form 
interactions that lead to tetramer formation. Interestingly, several of the residues involved in 
formation of the YefMMtb tetramer are homologous to YefMEc residues that interact with YoeBEc 
in the YefM-YoeBEc crystal structure (125), suggesting that stabilization of YefMMtb in this 
tetrameric complex by a small molecule or peptide could prevent interaction with YoeBMtb. 
However, it is also possible that tetramer formation could be an artifact of the crystallization 
conditions and therefore lack physiological relevance, as the crystal structure of the YefMMtb 
tetramer was obtained at low pH, which was found to induce dissociation of the YefM-YoeBMtb 
complex (125). Nevertheless, these results present the exciting possibility that small molecules or 
peptides could be able to stabilize YefM homologues in oligomeric configurations that are 
unable to interact with YoeB. 
Figure 1.6 Crystal structure of the YefMMtb tetramer (PDB ID 3CTO). YefMMtb monomers 
are depicted in yellow, magenta, green, and blue. A portion of the blue monomer was 
disordered in the crystal structure and is not shown here. N- and C-termini are labeled “N” 
and “C,” respectively. 
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1.4.3  YefM-YoeBSa1 and YefM-YoeBSa2 
The S. aureus YoeB homologues YoeBSa1 and YoeBSa2 were characterized via 
overexpression in E. coli. Both proteins possessed ribosome-dependent RNase activity similar to 
that of YoeBEc, and expression in the absence of their respective antitoxins induced growth arrest 
in E. coli (126), suggesting that YoeBSa1 and YoeBSa2 inhibit translation initiation and that 
artificial activation of YoeBSa1 or YoeBSa2 could have a bacteriostatic effect in S. aureus. There 
is significant sequence similarity among the YefM-YoeBEc, YefM-YoeBSa1, and YefM-YoeBSa2 
TA systems, and the catalytic residues responsible for the in vitro ribosome-dependent RNase 
activity of YoeBEc are conserved in YoeBSa1 and YoeBSa2 (Figure 1.7). Thus it is likely that 
YefM-YoeBSa1 and YefM-YoeBSa2 are structurally similar to YefM-YoeBEc. Consequently, these 
systems present ideal targets for both the toxin- and antitoxin-binding toxin activation strategies 
by the same reasoning applied to YefM-YoeBEc and YefMMtb. The aim of the research described 
in this thesis was to investigate activation of the YefM-YoeBSa1 and YefM-YoeBSa2 TA systems 
as a novel antibacterial strategy against S. aureus. 
 
 
 
Figure 1.7 Clustal W sequence alignments of A, YefMEc, YefMSa1, and YefMSa2; and B, 
YoeBEc, YoeBSa1, and YoeBSa2. Asterisks (*) denote positions with a single, fully conserved 
residue; colons (:) denote conservation between residues with strongly similar properties; and 
periods (.) denote conservation between residues with weakly similar properties. Residues 
highlighted in green are conserved and required for YoeBEc RNase activity. 
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1.5  SUMMARY AND OUTLOOK 
 There is a dire need for the development of new antibacterial strategies to address the 
growing problem of antibacterial resistance. A novel antibacterial strategy with considerable 
potential is the artificial activation of bacterial TA systems. The toxic proteins encoded by these 
systems have a variety of modes of action that could be exploited to inhibit growth or kill 
bacteria. This thesis describes investigation of the Staphylococcus aureus TA systems YefM-
YoeBSa1 and YefM-YoeBSa2 as novel, much-needed antibacterial targets in this increasingly 
drug-resistant pathogen. Chapter 2 describes the validation of the prevalence, conservation, and 
transcription of the yefM-yoeBSa1 and yefM-yoeBSa2 genes in clinical isolates of MRSA as well as 
efforts to use phage display to identify peptides that bind specifically to the YefMSa1 antitoxin. 
Chapter 3 describes the invention of a novel strategy for the expression of toxic proteins, the 
characterization of the RNase activity of YoeBSa1, and the development of a high-throughput 
assay that can be used to screen libraries of small molecules and peptides for activators of the 
YefM-YoeBSa1 TA system. 
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CHAPTER 2 
INVESTIGATION OF STAPHYLOCOCCUS AUREUS YEFMSA1 
AS AN ANTIBACTERIAL TARGET 
 
2.1  INTRODUCTION 
The efficacy of an antibacterial drug depends on the conservation and functionality of the 
drug target in pathogenic bacteria. Consequently, one of the preliminary requirements for 
validation of a bacterial toxin-antitoxin (TA) system as a potential antibacterial target is 
assessment of the presence and functionality of the TA system in the pathogen of interest. The 
first part of this thesis chapter describes PCR and RT-PCR screens that were performed on a 
diverse set of clinical MRSA isolates to detect the presence, conservation, and transcription of 
the yefM-yoeBSa1 and yefM-yoeBSa2 genes. 
Following establishment of the conservation and functionality of a potential drug target, 
the next step in target-based drug discovery is the identification of a molecule that exerts the 
desired effect on the target. As yefM-yoeBSa1 proved more amenable to manipulation using 
standard molecular biology techniques than yefM-yoeBSa2, YefM-YoeBSa1 was selected as a 
target for artificial activation. As discussed in Chapter 1, a TA system activator must be able to 
prevent formation of the TA complex and/or disrupt it after it has formed. Theoretically, a toxin 
activator could bind either to the toxin or to the antitoxin, but whether YefMSa1 or YoeBSa1 will 
provide a better target for an artificial activator of YefM-YoeBSa1 is unknown. The second part 
of this thesis chapter therefore describes evaluation of YefMSa1 as a target using phage display 
with libraries of T7 bacteriophage displaying randomized linear and cyclic peptides. 
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2.2  RESULTS 
2.2.1  Prevalence and Conservation of yefM-yoeBSa1 and yefM-yoeBSa2 in MRSA Clinical Isolates 
The total DNA of 78 clinical isolates of MRSA previously obtained from three Illinois 
hospitals and the Network on Antimicrobial Resistance in S. aureus (NARSA) (1) was probed 
for the presence of yefM-yoeBSa1 and yefM-yoeBSa2 using PCR with intragenic specific primers 
(Figure 2.1). (See Table 2.1 at the end of this chapter for a complete list of primers used in this 
study.) The yefM-yoeBSa1 and yefM-yoeBSa2 genes were present in 99% (77 out of 78) of the 
clinical isolates (see Table 2.2 at the end of this chapter). Approximately 10% of the PCR 
products were subjected to DNA sequencing, and the sequences were aligned with the reference 
genome from the S. aureus COL strain using CLUSTAL W (2) and compared with yefM-yoeBSa1 
and yefM-yoeBSa2 loci from published S. aureus genomes using BLAST (3). (See Figures 2.17 
and 2.18 at the end of this chapter.) The yefM-yoeBSa1 PCR products had greater than 97% 
identity with the yefM-yoeBSa1 genes in 29 of the 30 genomes containing that locus, while the 
yefM-yoeBSa2 PCR products had at least 96% identity with the yefM-yoeBSa2 genes in all 26 
genomes containing that locus. These results indicate that yefM-yoeBSa1 and yefM-yoeBSa2 are 
widespread and highly conserved in clinical MRSA isolates.  
 
 Figure 2.1 Primers used to amplify portions of the yefM-yoeBSa1 and yefM-yoeBSa2 operons 
for PCR and RT-PCR were designed from the S. aureus COL genome. 
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2.2.2  Transcription of yefM-yoeBSa1 and yefM-yoeBSa2 in MRSA Clinical Isolates 
To investigate the transcription of yefM-yoeBSa1 and yefM-yoeBSa2 in MRSA, RT-PCR 
was performed on total RNA from eight isolates using the same primers used in the PCR screen. 
yefM-yoeBSa1 and yefM-yoeBSa2 were transcribed as bicistronic messages in each of the strains 
(Figure 2.2). No PCR products were detected in the absence of reverse transcriptase, indicating 
the absence of DNA contamination. These results suggest that yefM-yoeBSa1 and yefM-yoeBSa2 
are transcribed in clinical MRSA isolates and provide further support for their investigation as 
novel antibacterial targets. 
 
 
2.2.3  Cloning, Expression, and Purification of (His)6YefMSa1 
The yefMSa1 gene was amplified from genomic DNA isolated from MRSA strain NRS3 
from NARSA and cloned into the pET-28a vector with an N-terminal (His)6-tag to facilitate 
overexpression and purification of the YefMSa1 protein (Figure 2.3). Sequencing analysis 
identified the 370 bp insert as the yefMSa1 gene and confirmed that the gene was in-frame. 
Figure 2.2 RT-PCR analysis of transcription of yefM-yoeBSa1 (upper panels) and yefM-
yoeBSa2 (lower panels) in MRSA clinical isolates. Lane M: 100 bp DNA ladder (1517, 1200, 
1000, 900, 800, 700, 600, 500, 400, 300, 200, and 100 bp, NEB). (+) and (–) denote the 
inclusion or exclusion, respectively, of reverse transcriptase in the reaction mix. Clinical 
isolates are identified by strain number.  
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The resulting plasmid was transformed into E. coli BL21 and expression was induced 
with IPTG under standard conditions. The fusion protein was purified from clarified lysate under 
native conditions using nickel-nitrilotriacetic acid (Ni-NTA) agarose metal-affinity 
chromatography and standard buffers. SDS-PAGE analysis of the purified protein indicated that 
(His)6-YefMSa1 eluted from the resin in high yield and purity (Figure 2.4).  
 
 
 
    RBS        Start             His6-tag 
....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
         10        20        30        40        50        60        70 
AAGAAGGAGATATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGC 
                                        Native YefMSa1 start 
....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
         80        90        100       110       120       130       140 
AGCCATATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGCGGATCCATGATTATTAAAAATTATTCAT 
 
....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
         150       160       170       180       190       200       210 
ACGCTCGACAGAATTTAAAGGCACTTATGACAAAAGTAAATGATGATAGTGATATGGTAACTGTAACATC 
 
....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
         220       230       240       250       260       270       280 
TACTGATGATAAAAACGTAGTAATCATGTCAGAATCAGATTATAACTCCATGATGGAAACACTTTACCTC 
 
....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
         290       300       310       320       330       340       350 
CAACAGAACCCAAATAATGCTGAACACTTAGCTCAATCAATTGCAGATCTAGAACGTGGGAAAACTATAA 
             YefMSa1 stop 
....|....|....|....| 
         360       370 
CGAAAGATATAGATGTATAA 
Figure 2.3 Nucleotide sequence of pET-28a-yefMSa1. A (His)6-tag is encoded upstream of the 
yefMSa1 gene. IPTG induces expression of (His)6YefMSa1. 
Figure 2.4 SDS-PAGE analysis of (His)6YefMSa1 expression and purification. Lane M: 
Kaleidoscope protein standards (Bio-Rad). Lanes 1 and 2: Expression culture lysate 
immediately prior to induction with IPTG and four hours after induction, respectively. Lane 
3: Unclarified lysate. Lane 4: Clarified lysate. Lane 5: Ni-NTA column flowthrough. Lane 6: 
Lysis buffer wash. Lane 7: 60 mM imidazole wash. Lane 8: Elution with 500 mM imidazole. 
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2.2.4  Circular Dichroism Analysis of (His)6YefMSa1 
Circular dichroism (CD) is the differential absorption of left and right circularly polarized 
light by optically active chiral molecules. CD in the far ultraviolet range between 190 and 260 
nm is commonly used to predict the secondary structural content of proteins (4). The published 
CD spectra and calculated secondary structural content of YefMSa1 homologues YefMEc from E. 
coli (5) and YefMSpn from Streptococcus pneumoniae (6) suggest that both possess significant 
secondary structure in the absence of YoeBEc and YoeBSpn, respectively (Figure 2.5). 
 
 
 
Figure 2.5 CD analysis of YefMSa1 homologues. A, CD spectrum of YefMEc (adapted from 
ref. 5 with permission from Oxford University Press). B, CD spectrum of YefMSpn (adapted 
from ref. 6 with permission from the American Society for Microbiology). C, Secondary 
structural content of YefMEc and YefMSpn calculated from CD spectra in A and B, 
respectively. 
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To evaluate the secondary structural content of (His)6YefMSa1, a CD spectrum was 
obtained using standard conditions. Secondary structural content was estimated from the raw 
data using the K2D algorithm (7) available on the online DICHROWEB server (8). The CD 
spectrum of (His)6YefMSa1 (Figure 2.6C) resembles those of YefMEc and YefMSpn (Figure 2.5A 
Figure 2.6 Secondary structural analysis of (His)6YefMSa1. A, Jpred secondary structure 
prediction for (His)6-YefMSa1. Residues predicted to occur in α-helices, β-sheets, and random 
coils are designated “α,” “β,” and “–” respectively. B, Jpred secondary structure prediction for 
(His)6YefMSa1 modified for predicted disorder at the C-terminus in the absence of YoeBSa1. 
C, CD spectrum of (His)6-YefMSa1. D, Secondary structural content of (His)6YefMSa1 
calculated from Jpred predictions in A and B and experimental CD spectrum in C. 
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and B), and the calculated secondary structural content of (His)6YefMSa1 is similar to that of 
YefMSpn (Figures 2.5C, 2.6D) but differs from that predicted using the secondary structure 
prediction tool Jpred (9) (Figure 2.6A, D). However, if the C-terminus of (His)6YefMSa1 is 
allowed to be disordered, as would be predicted in the absence of YoeBSa1, the Jpred secondary 
structure prediction can be modified to yield predicted secondary structural content very similar 
to that measured experimentally (Figure 2.6B, D). These results indicate that (His)6YefMSa1 is at 
least partially folded in the absence of YoeBSa1. 
 
2.2.5  Gel Filtration Analysis of (His)6YefMSa1 
Gel filtration (GF) chromatography is commonly used to separate macromolecules by 
hydrodynamic volume based on differential ability to access pores in beads or resin made of a 
cross-linked polymeric matrix. Molecules that are smaller than the pores are able to diffuse into 
and out of the pores in the resin, which impedes their progress through the chromatography 
column. In contrast, molecules larger than the pores are unable to enter the pores in the resin, so 
their path through the resin is much shorter and they elute faster (10). Consequently, for 
macromolecules of similar shape, elution volume is inversely proportional to size (11). GF is 
often used to evaluate the oligomeric status of a protein by comparison of its elution volume to 
those of known standards. As YefMEc forms a dimer in the crystal structure of the YefM-YoeBEc 
complex (12) and YefMMtb crystallizes as a homotetramer (13), YefMSa1 may also undergo 
oligomerization, which would provide further support for the existence of structure in the 
absence of YoeBSa1. 
Purified (His)6YefMSa1 was therefore subjected to GF on a Superdex 75 column. Bovine 
serum albumin (BSA), carbonic anhydrase (CA), and aprotinin were separated on the same 
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column under identical conditions, and a calibration curve of log molecular weight versus elution 
volume was constructed using these proteins as standards (Figure 2.7A). The linear fit of the 
calibration curve was used to convert the elution volume of (His)6YefMSa1 to an apparent 
molecular weight of 43 kDa (Figure 2.7B). As the molecular weight of monomeric 
(His)6YefMSa1 is 12.8 kDa, the calculated molecular weight is consistent with the formation of an 
oligomeric species but is too high for a dimer and too low for a tetramer, which would be 
predicted based on the crystal structures of YefM-YoeBEc (12) and YefMMtb (13). However, all 
of the standards used for the calibration curve are compact, well-folded, globular proteins. In 
contrast, YefMEc and YefMMtb have elongated rather than spherical conformations in their 
respective crystal structures. Additionally, both the N-terminal (His)6-tag and the C-terminus of 
(His)6YefMSa1 are predicted to be disordered (Figure 2.6B). Shape exerts significant influence 
on migration through gel filtration media (11). Consequently, the GF elution profile of 
(His)6YefMSa1 could be indicative of the formation of a (His)6YefMSa1 dimer with an elongated 
conformation and/or disordered N- and C-termini, which would retard its progress through the 
column to a greater extent than would be expected if it had a more compact, globular fold. 
Further investigation into the oligomeric status of (His)6YefMSa1 could be carried out using 
chemical cross-linking followed by SDS-PAGE analysis to confirm this hypothesis (14). 
However, at minimum, these results provide evidence that (His)6YefMSa1 undergoes 
oligomerization in the absence of YoeBSa1 and suggest it may be possible to identify a small 
molecule or peptide that could be used to stabilize oligomeric YefMSa1 in a conformation that 
would be unable to interact with YoeBSa1. 
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2.2.6  Construction of T7 Phage Libraries 
Based on the crystal structure of the YefM-YoeBEc complex (12), binding between 
YefMSa1 and YoeBSa1 is predicted to be mediated by an extensive protein-protein interface, 
suggesting that peptides would be better suited than small molecules to disrupt or prevent the 
YefM-YoeBSa1 interaction. Phage display technology was developed to identify peptides or 
proteins that bind to a target molecule. A library of DNA sequences is inserted into a 
bacteriophage genome such that the polypeptide encoded by the DNA will be fused to the N- or 
C-terminus of one of the phage coat proteins. The recombinant genomic DNA is introduced into 
bacteriophage, and the library is amplified by infecting a bacterial host. Libraries of 10
8
-10
9
 
independent clones can be produced, allowing a vast number of sequences to be displayed for 
screening against a target molecule. Selection of polypeptides that bind to the target is achieved 
Figure 2.7 GF analysis of (His)6YefMSa1. A, Calibration plot of log MW versus elution 
volume for molecular weight standards BSA, CA, and aprotinin. B, Elution volume data used 
to calculate the apparent molecular weight of (His)6YefMSa1. 
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through an iterative process termed “biopanning” (Figure 2.8). The phage library is incubated 
with the target to allow the displayed polypeptides to bind to the target. Non-specifically bound 
phage are washed away, and specifically bound phage are eluted and amplified in the bacterial 
host. This process is repeated to enrich the phage pool for polypeptides that bind to the target. 
After several rounds of selection, sequence analysis of the DNA encoding the polypeptide insert 
from several clones is used to identify polypeptide sequences that bind to the target (15). 
Two sets of T7 phage display libraries were constructed to assess the abilities of both 
linear and cyclic peptides to bind to YefMSa1. In “415” libraries, peptides are displayed on all 
415 copies of T7 capsid protein 10B. In “10” libraries, peptides are displayed on only 5 to 15 
copies of T7 capsid protein 10B. Each set of libraries comprises one linear library of randomized 
9-residue peptides (X9) and three cyclic libraries of randomized 7-, 9-, and 10-residue peptides 
flanked by cysteines (CX7C, CX9C, and CX10C, respectively), which undergo disulfide bond 
formation in the absence of reducing agents. The DNA sequences for the peptides used in each 
library were constructed using degenerate NNK codons, where N is a 25% mixture of adenine, 
Figure 2.8 Schematic illustration of biopanning. The phage library is incubated with the 
immobilized target to allow binding of the displayed polypeptide. Non-specifically bound 
phage are removed by washing prior to elution of specifically bound phage and amplification 
in the bacterial host. This process is repeated to select and amplify phage-displayed 
polypeptides specific for the target of interest. 
41 
 
cytosine, guanine, and thymine, and K is a 50% mixture of guanine and thymine. The use of 
NNK codons instead of NNN codons reduces the number of possible codons from 64 to 32 and 
eliminates 2 of 3 stop codons while encoding all 20 canonical amino acids, thereby improving 
the diversity of NNK libraries relative to NNN libraries (16). The sequence, average number of 
peptides displayed on each phage, and diversity of each library are shown in Table 2.3 at the end 
of this chapter. Although the diversity achieved within each library is significantly lower than the 
theoretical possible diversity, each library displays 10
6
-10
7
 unique peptides, which is similar to 
the number of compounds used in many high-throughput screens. These libraries were used in a 
series of twelve different biopan experiments with (His)6YefMSa1 as a target. 
 
2.2.7  T7 Phage Display with (His)6YefMSa1 
 Twelve biopan experiments were performed to identify peptides that specifically bind to 
(His)6YefMSa1. 
 
2.2.7.A  Biopans 1-4 
In Biopans 1-4, the 415-X9 library was screened. Four rounds of selection were 
performed in the presence (+YefM) or absence (–YefM) of immobilized (His)6YefMSa1. 
(His)6YefMSa1 was immobilized to Ni-NTA agarose in rounds 1 and 3 and magnetic Ni-NTA 
resin in rounds 2 and 4. SDS-PAGE analysis of the supernatant recovered after immobilization 
of (His)6YefMSa1 was used to confirm saturation of the resin (Figure 2.9). 
The resin was then blocked with 5% BSA in rounds 1 and 3 or 5% casein in rounds 2 and 
4. The solid support and the blocking agent were alternated between successive rounds to 
minimize selection for peptides that bound to the solid support or the blocking agent. To further 
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increase the stringency of selection, the amount of solid support used was decreased from 5 µl in 
rounds 1 and 2 to 2.5 µl in rounds 3 and 4. The immobilized protein was incubated with the 415-
X9 library at a multiplicity of 100 (round 1) or at constant volume (rounds 2-4) for 25, 22, 18, or 
15 min, followed by 5, 6, 7, or 8 washes using 0.2% TBST (Tris-buffered saline, pH 7.5, 0.2% 
Tween-20) in rounds 1, 2, 3, and 4, respectively. The remaining phage were eluted with 500 mM 
imidazole (Biopans 1 and 2) or 1% SDS (Biopans 3 and 4) and amplified by infection of E. coli 
BL21. Subsequent rounds were performed using the same input volume of phage as round 1. In 
the first round of Biopans 2 and 4, the phage library was “precleared” by incubation with the 
blocked solid support prior to incubation with immobilized (His)6YefMSa1 as described above. A 
plaque assay was performed using phage amplified from round 4. Fifteen plaques from +YefM 
biopans and five (Biopans 1 and 2) or ten (Biopans 3 and 4) plaques from –YefM biopans were 
selected, the DNA sequence encoding the displayed peptide was amplified by PCR, and the PCR 
products were subjected to DNA sequence analysis. The resulting sequences and calculated 
sequence logos are shown in Figure 2.10. Although several sequencing reactions failed for 
Figure 2.9 SDS-PAGE analysis of Ni-NTA resin saturation in Biopans 1-4. Lane 1: 
Kaleidoscope protein standards (Bio-Rad). Lane 2: (His)6YefMSa1 (1 mg/ml) prior to 
immobilization on Ni-NTA resin. Lanes 3-6: (His)6YefMSa1 in supernatant recovered after 
immobilization on Ni-NTA resin in rounds 1-4, respectively. 
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Figure 2.10 Sequences and sequence logos of peptides from Biopans 1-4 performed in the 
presence (+YefM) and absence (–YefM) of (His)6YefMSa1. 
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unknown reasons, overall trends can still be observed from the sequences of plaques isolated 
from each biopan. 
In Biopans 1 and 2, elution was performed with 500 mM imidazole to release both 
(His)6YefMSa1 and specifically bound phage from the solid support. It is possible that these 
elution conditions could cause selection for peptides enriched in histidine residues that are able 
to chelate Ni-NTA. Biopans 1 and 2 differed only in that a preclear round was performed prior to 
incubation with (His)6YefMSa1 in the first round of Biopan 2 but not in Biopan 1. The goal of the 
preclear round was to minimize selection for peptides that bound specifically to the solid support 
or to the blocking agent rather than (His)6YefMSa1. Interestingly, eight of twelve peptides from 
Biopan 2+YefM contain one or more histidine residues, while only two of ten peptides from 
Biopan 1+YefM contain one or more histidine residues, and three of five peptides from both 
Biopans 1 and 2–YefM contain one or more histidines. These results suggest that the preclear 
used in Biopan 2 did not improve selection against peptides binding to the solid support. 
In contrast to Biopans 1 and 2, elution was performed with 1% SDS in Biopans 3 and 4 to 
release specifically bound phage from (His)6YefMSa1. A preclear round was performed prior to 
incubation with (His)6YefMSa1 in the first round of Biopan 4 but not in Biopan 3. No selection 
for peptides enriched in histidine residues was observed in biopans performed in the presence of 
(His)6YefMSa1, as only one of thirteen peptides from Biopan 3+YefM and three of fifteen 
peptides from Biopan 4+YefM contained one or more histidine residues. However, five of eight 
peptides from Biopan 3–YefM and seven of ten peptides from Biopan 4–YefM contained one or 
more histidine residues. These results suggest that elution with 1% SDS does not cause selection 
for peptides that bind to the solid support in the presence of (His)6YefMSa1 but that it may in the 
absence of (His)6YefMSa1. 1% SDS was used as the eluent in all subsequent biopan experiments. 
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No consensus sequence was observed in any of the +YefM biopans. The only sequence 
obtained more than once was THLNRKHVS from Biopan 1–YefM, but this peptide was not 
selected in any of the other –YefM biopans. Aside from the differences in histidine content 
discussed above, glycine and arginine residues were enriched in peptides from all four biopans 
regardless of whether or not (His)6YefMSa1 was present. Failure to observe the emergence of a 
consensus sequence in the presence of (His)6YefMSa1 as well as the similarity of peptides 
selected in the presence and absence of (His)6YefMSa1, suggests that the selection conditions 
used in Biopans 1-4 were not stringent enough to isolate peptides binding specifically to 
(His)6YefMSa1. 
 
2.2.7.B  Biopans 5-6 
Biopans 5 and 6 were designed to increase the stringency of selection by increasing the 
duration of washes and the amount of Tween in each wash. The 415-X9 library was screened in 
Biopan 5, and the 415-CX7C, -CX9C, and -CX10C libraries were pooled and screened in Biopan 
6. A preclear was performed with 50 µl blocked solid support prior to incubation with 
(His)6YefMSa1 in each round. Magnetic Ni-NTA resin (10, 5, 2.5, and 1.25 µl suspension in 
rounds 1, 2, 3, and 4, respectively) was used as the solid support. As for Biopans 1-4, SDS-
PAGE analysis of the supernatant recovered after immobilization of (His)6YefMSa1 was used to 
confirm saturation of the resin (Figure 2.11). 
Following immobilization of (His)6YefMSa1, the solid support was blocked with 5% skim 
milk in rounds 1 and 3 or 5% BSA in rounds 2 and 4. The immobilized protein was then 
incubated with the phage library at a multiplicity of 100 (round 1) or at constant volume (rounds 
2-4) for 30, 25, 20, or 15 min, followed by 5, 6, 7, or 8 washes of 2, 5, 8, or 11 min using 0.2, 
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0.5, 0.8, or 1.1% TBST in rounds 1, 2, 3, and 4, respectively. The remaining phage were eluted 
using 1% SDS and amplified by infection of E. coli BL21, and subsequent rounds were 
performed using the same input volume of phage as round 1. A plaque assay was performed 
using phage amplified from round 4. Fifteen plaques from ±YefM biopans were selected, the 
DNA sequence encoding the displayed peptide was amplified by PCR, and the PCR products 
were subjected to DNA sequence analysis. The resulting sequences and sequence logos are 
shown in Figure 2.12. 
Three of fifteen peptides from Biopan 5+YefM have the sequence GRGVASEGG, and 
two have the sequence VRGRAGRGV. Each of these peptides contains several glycines and at 
least one valine, arginine, and alanine. However, most peptides from Biopan 5–YefM contain 
similar numbers of glycine, arginine, valine, and alanine residues. The similarity of peptides 
from Biopans 5±YefM suggests that consensus peptides from Biopan 5+YefM do not bind 
specifically to (His)6YefMSa1. 
 
Figure 2.11 SDS-PAGE analysis of Ni-NTA resin saturation in Biopans 5 and 6. Lane 1: 
Kaleidoscope protein standards (Bio-Rad). Lane 2: (His)6YefMSa1 (1 mg/ml) prior to 
immobilization on Ni-NTA resin. Lanes 3-6: (His)6YefMSa1 in supernatant recovered after 
immobilization on Ni-NTA resin in rounds 1-4, respectively. 
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Figure 2.12 Sequences and sequence logos of peptides from Biopans 5 and 6 performed in 
the presence (+YefM) and absence (–YefM) of (His)6YefMSa1. 
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None of the fifteen peptides from Biopan 6+YefM are from the CX7C library, two are 
from the CX9C library, five are from the CX10C library, two contain internal stop codons 
resulting in premature truncation and failure to cyclize, and five lack the insert encoding the 
peptide, so only the wild-type coat protein was displayed. Two of the five CX10C peptides from 
Biopan 6+YefM have the sequence CPPRAGTRKTGC. Two of fifteen peptides from Biopan 6–
YefM are from the CX7C library, six are from the CX9C library, four are from the CX10C library, 
and three contain internal stop codons. The low numbers of CX7C peptides from Biopans 
6±YefM suggests that larger cyclic peptides are preferentially selected under these biopan 
conditions. Once again, peptides selected in both the presence and absence of (His)6YefMSa1, 
including the CX10C peptide CPPRAGTRKTGC observed twice in Biopan 6+YefM, are 
enriched in hydrophobic and basic residues, suggesting that none of the Biopan 6+YefM peptides 
binds specifically to (His)6YefMSa1. None of the peptides from Biopans 5 or 6+YefM was 
pursued for further characterization.  
 
2.2.7.C  Biopans 7-8 
One possible explanation for the similar characteristics of peptides selected in Biopans 1-
6 is that the Ni-NTA solid support used for target immobilization influenced selection in the 
presence and absence of (His)6YefMSa1, causing selection of peptides with hydrophobic and 
basic residues. To test this hypothesis, a different immobilization strategy was utilized in 
Biopans 7 and 8. There was additional concern that the high copy number of peptides displayed 
in the 415 libraries used in Biopans 1-6 would result in avidity effects and selection for weakly 
binding peptides with low individual affinity for (His)6YefMSa1. It was hypothesized that phage 
libraries with lower copy numbers of displayed peptides would eliminate potential avidity 
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effects. To evaluate the potential contribution of avidity to the selection process, the 415-X9, -
CX7C, -CX9C, and -CX10C libraries were pooled and used in Biopan 7, and the 10-X9, -CX7C, -
CX9C, and -CX10C libraries were pooled and used in Biopan 8. 
(His)6YefMSa1 was adsorbed to a Nunc Maxisorp plate, followed by blocking with 5% 
skim milk in odd-numbered rounds and 5% BSA in even-numbered rounds. The immobilized 
protein was then incubated with the phage library at a multiplicity of 100 (round 1) or at constant 
volume (rounds 2-5) for 1 h, followed by 5, 10, 15, 20, and 25 washes using 0.2% TBST in 
rounds 1, 2, 3, 4, and 5, respectively. The remaining phage were eluted using 1% SDS and 
amplified by infection of E. coli BL21 (Biopan 7) or BLT5615 (Biopan 8), and subsequent 
rounds were performed using the same input volume of phage as round 1. A plaque assay was 
performed using phage amplified from round 5. Fifteen plaques from ±YefM biopans were 
selected, the DNA sequence encoding the displayed peptide was amplified by PCR, and the PCR 
products were subjected to DNA sequence analysis. The resulting sequences and sequence logos 
are shown in Figure 2.13. 
Two of thirteen peptides from Biopan 7+YefM have the sequence CSGGRRKAC, and 
two have the sequence MSVCRKKGL. Seven peptides are from the 415-X9 library, three are 
from the 415-CX7C library, two are from the 415-CX9C library, and one sequence lacked the 
peptide insert. Two of fifteen peptides from Biopan 7–YefM have the sequence 
CGSRGRKVGGC, nine are from the 415-X9 library, three are from the 415-CX9C library, and 
three contain internal stop codons resulting in premature truncation and, in one case, failure to 
undergo cyclization. Interestingly, none of the peptides from Biopans 7±YefM are from the 415-
CX10C library. As all of the peptides selected in Biopans 7±YefM are similarly enriched in basic 
and hydrophobic residues, none was pursued for further characterization. Furthermore, the  
50 
 
 Figure 2.13 Sequences and sequence logos of peptides from Biopans 7 and 8 performed in 
the presence (+YefM) and absence (–YefM) of (His)6YefMSa1. 
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similarity between peptides from Biopans 7±YefM and peptides from Biopans 1-6±YefM, which 
were performed using Nunc Maxisorp plates and Ni-NTA resin as solid support, respectively, 
indicates that selection for peptides enriched in hydrophobic and basic residues is independent of 
the solid support used. 
Four of fifteen peptides from Biopan 8+YefM are from the 10-X9 library, two are from 
the 10-CX7C library, eight are from the 10-CX9C library, and one is from the 10-CX10C library. 
Three of fourteen peptides from Biopan 8–YefM are from the 10-X9 library, seven are from the 
10-CX7C library, two are from the 10-CX9C library, one is from the 10-CX10C library, and one 
contains an internal stop codon resulting in premature truncation and failure to undergo 
cyclization. Several sequences contain mutated stop codons and encode peptides of extended 
length. None of the peptides from Biopan 8+YefM occurs more than once, and peptides from 
Biopans 8±YefM contain similar numbers of basic and hydrophobic residues. These results 
suggest that none of the peptides from Biopan 8+YefM binds specifically to (His)6YefMSa1 and 
that avidity effects do not contribute to selection for peptides with basic and hydrophobic 
residues in both the presence and absence of (His)6YefMSa1. None of the peptides from Biopan 8 
was pursued for further characterization. 
 
2.2.7.D  Biopans 9-10 
Another potential explanation for failure to identify peptides specifically binding to 
(His)6YefMSa1 in Biopans 1-8 is that solid-phase biopanning induces unfolding or misfolding of 
(His)6YefMSa1 upon binding to Ni-NTA, adsorption to polystyrene, and/or incubation with 
blocking agents prior to incubation with phage. If (His)6YefMSa1 does remain properly folded 
following immobilization and blocking, the small size of (His)6YefMSa1 and the presence of the 
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larger biomolecules used as blocking agents may prohibit specific interaction of phage-displayed 
peptides with (His)6YefMSa1. It was therefore hypothesized that solution-phase biopanning prior 
to immobilization could enable selection of peptides that recognize and stabilize (His)6YefMSa1 
in a native conformation with a low affinity for YoeBSa1. 
Consequently, Biopans 9 and 10 were performed using solution-phase biopanning 
methodology. Biopan 9 screened the 10-X9 library, and Biopan 10 screened the pooled 10-CX7C, 
-CX9C, and -CX10C libraries. Control biopans in the absence of (His)6YefMSa1 were not 
performed for Biopans 9 and 10. Six rounds of biopanning were completed, with preclears 
included prior to rounds 2, 4, and 6. (His)6YefMSa1 was incubated with the phage library at a 
multiplicity of 100 (round 1) or at constant volume (rounds 2-6) for 30, 25, 20, and 15 min, in 
rounds 1, 2, 3, and 4-6, respectively. Imidazole was then added to a final concentration 40 mM to 
prevent binding of histidine-rich peptides to the solid support, and the (His)6YefMSa1/phage 
mixture was incubated with a suspension of magnetic Ni-NTA resin pre-blocked with 5% BSA 
in odd rounds or a 50% slurry of Ni-NTA agarose pre-blocked with 5% skim milk in even 
rounds. Following immobilization of (His)6YefMSa1 and bound phage to the solid support, non-
specifically bound phage were removed with 10 washes containing 0.2, 0.5, 0.8, and 1.1% 
Tween-20 in rounds 1, 2, 3, and 4-6, respectively. The remaining phage were eluted using 1% 
SDS and amplified by infection of E. coli BLT5615. Subsequent rounds of biopanning were 
performed using the same input volume of phage as round 1. Plaque assays were performed 
using phage amplified from rounds 4 and 6. Fifteen plaques were selected, the DNA sequence 
encoding the displayed peptide was amplified by PCR, and the PCR products were subjected to 
DNA sequence analysis. The resulting sequences and sequence logos are shown in Figure 2.14. 
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 Figure 2.14 Sequences and sequence logos of peptides from Biopans 9 and 10 performed in 
the presence (+YefM) and absence (–YefM) of (His)6YefMSa1. 
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Interestingly, four out of twelve peptides from Biopan 9 had the sequence GGRGSQPGG 
after round 4, and five out of eleven had the same sequence after round 6. The peptide 
HGLGRSALV was seen once in both the fourth and sixth rounds. The persistence of these 
peptides without further enrichment over three rounds of biopanning is consistent with a 
mathematical model suggesting that biopanning beyond three or four rounds does not results in 
further enrichment of specifically binding peptides (17). 
None of the peptides from Biopan 10 appeared more than once after either four or six 
rounds, and none of the same peptides were observed between rounds four and six with the 
exception of the wild-type coat protein sequence, which was obtained once in each round. None 
of the cyclic peptide libraries dominated the peptides from round 4, but four of seven peptides 
from round 6 belonged to the CX9C library. The observed dominance of the CX9C library is 
similar to that seen in Biopan 8+YefM. 
Although control biopans in the absence of (His)6YefMSa1 were not carried out for 
Biopans 9 and 10, peptides from Biopans 9 and 10 contain similar proportions of basic and 
hydrophobic residues as Biopans 1-8±YefM, which suggests that solution-phase biopanning does 
not significantly improve the ability to identify peptides specifically binding to (His)6YefMSa1. 
 
2.2.7.E  Biopans 11-12 
The lack of secondary structure and tendency to unfold of (His)6YefMSa1 was pursued as 
a final potential explanation for the failure to select peptides appearing significantly different 
between biopans performed in the presence and absence of (His)6YefMSa1. It was hypothesized 
that the high concentrations of Tween-20 employed to increase the stringency of selection during 
incubation with phage and washes to remove non-specifically bound phage could cause 
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(His)6YefMSa1 to unfold, thereby releasing or preventing the binding of peptides specific for 
(His)6YefMSa1 and instead causing selection for peptides binding to the solid support or blocking 
agent. To evaluate the effect of Tween-20 on the secondary structure of (His)6YefMSa1, CD 
spectra of (His)6YefMSa1 were obtained in concentrations of Tween-20 identical to those used in 
Biopans 1-10, and the secondary structural content was calculated using the K2D algorithm (7) 
available on the online DICHROWEB server (8) (Figure 2.15). The spectra were 
superimposable regardless of Tween-20 concentration, and the calculated secondary structural 
content was very similar to that calculated for (His)6YefMSa1 alone (Figure 2.6), suggesting that 
Tween-20 does not cause unfolding of (His)6YefMSa1 in solution. 
 
Figure 2.15 CD analysis of (His)6YefMSa1 structure in Tween-20. A, CD spectra of 
(His)6YefMSa1 in 20 mM sodium phosphate, pH 7.0, containing 0.1% (blue), 0.2% (red), 0.5% 
(green), 0.8% (purple), and 1.1% (teal) Tween-20. B, Secondary structural content of 
(His)6YefMSa1 calculated from CD spectra in A. Spectra and secondary structural content 
were calculated from raw data using the K2D algorithm on the online DICHROWEB server. 
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However, it remained possible that Tween-20 could induce unfolding of (His)6YefMSa1 
when bound to the solid support in the presence of a blocking agent. To explore this hypothesis, 
Biopans 11 and 12 screened the 10-X9 library using TBS and 0.1% TBST, respectively, for all 
phage incubation and washing steps. Four rounds of biopanning were performed. (His)6YefMSa1 
was incubated with the phage library at a multiplicity of 100 (round 1) or at constant volume 
(rounds 2-4) for 30 min. Imidazole was then added to a final concentration 40 mM to prevent 
binding of histidine-rich peptides to the solid support, and the (His)6YefMSa1/phage mixture was 
incubated with a suspension of magnetic Ni-NTA resin. Following immobilization of 
(His)6YefMSa1 and specifically bound phage, non-specifically bound phage were removed with 
10 washes of TBS (Biopan 11) or 0.1% TBST (Biopan 12). The remaining phage were eluted 
using 1% SDS and amplified by infection of E. coli BLT5615, and subsequent rounds were 
performed using the same input volume of phage as round 1. A preclear using 50 µl blocked 
solid support was included prior to incubation with (His)6YefMSa1 in rounds 2-4. Plaque assays 
were performed using phage amplified from round 4. Fifteen plaques from ±YefM biopans were 
selected, the DNA sequence encoding the displayed peptide was amplified by PCR, and the PCR 
products were subjected to DNA sequence analysis. The resulting sequences and sequence logos 
are shown in Figure 2.16. 
None of the peptides from Biopans 11 and 12 was obtained more than once, suggesting 
that eliminating or reducing Tween-20 from the phage incubation and washing procedures 
reduces the selection stringency to too great a degree to allow selection for specifically binding 
peptides to take place. Taken together with the CD data (Figure 2.15), these results indicate that 
Tween-20 is not responsible for the failure to identify peptides that specifically bind to 
(His)6YefMSa1 in Biopans 1-12. 
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2.3  DISCUSSION 
Expression of the YoeBSa1 and YoeBSa2 toxins in the absence of their cognate antitoxins, 
YefMSa1 and YefMSa2, respectively, was previously found to induce growth arrest in E. coli (18), 
suggesting that artificial activation of YoeBSa1 or YoeBSa2 in MRSA could provide a novel 
antibacterial strategy to combat this increasingly drug-resistant pathogen. The presence, 
Figure 2.16 Sequences and sequence logos of peptides from Biopans 11 and 12 performed in 
the presence (+YefM) and absence (–YefM) of (His)6YefMSa1. 
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conservation, and transcription of the yefM-yoeBSa1 and yefM-yoeBSa2 genes have now been 
confirmed in a diverse collection of MRSA clinical isolates, providing additional justification for 
the investigation of these systems as novel antibacterial targets. 
One possible strategy for artificial toxin activation involves the use of a small molecule 
or peptide to sequester the antitoxin and prevent it from interacting with the toxin. The YefMSa1 
antitoxin was investigated as a candidate for this strategy using phage display. Twelve biopan 
experiments were performed using (His)6YefMSa1 as a target. Although a few peptides were 
identified more than once in individual biopan experiments, the same peptides were never 
rediscovered in other biopan experiments performed using the same libraries under different 
conditions, which would have been expected if these peptides were truly able to specifically bind 
to (His)6YefMSa1. Additionally, the majority of peptides obtained from biopans performed in 
both the presence and the absence of (His)6YefMSa1 were enriched in basic and hydrophobic 
residues, suggesting that none of these peptides interacted specifically with (His)6YefMSa1. 
The underlying cause for the selection of similar peptides in biopans performed in both 
the presence and absence of (His)6YefMSa1 remains unclear. One possible explanation is that 
such a peptide was not present in the phage libraries used in biopan experiments. These libraries 
were constructed using commercially available kits. Although conditions were optimized to 
maximize the number of primary recombinants, each library contained a significantly lower 
number of independent clones than required to cover every possible peptide sequence (see Table 
2.3 at the end of this chapter). Phage libraries with much greater diversity are commercially 
available. For example, each of the Ph.D.-7, -C7C, and -12 libraries from New England Biolabs 
contains >10
9
 independent clones, which is sufficient to encode all of the possible 7-residue 
sequences for the first two libraries and a small fraction (~5 × 10
-5
 %) of the possible 12-residue 
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sequences for the third. Thus if there exists a linear or cyclic 7-residue peptide that will 
specifically bind to YefMSa1, it will likely be encoded by the Ph.D.-7 or -C7C libraries, 
respectively, and it may be possible to identify it by biopanning with these libraries against 
(His)6YefMSa1. 
An alternative explanation for the inability to identify a (His)6YefMSa1-specific peptide in 
biopan experiments is that the structure or lack thereof of (His)6YefMSa1 precluded specific 
binding of phage-displayed peptides. In particular, the lengthy 36-residue N-terminal tag of 
(His)6YefMSa1 may have prevented or interfered with proper folding or with binding of phage-
displayed peptides to (His)6YefMSa1. Proper folding of (His)6YefMSa1 could be assessed by 
evaluating its ability to bind to YoeBSa1 in pulldown experiments and to inhibit YoeBSa1 in 
activity assays. Unfortunately, at the time that biopanning experiments with (His)6YefMSa1 were 
being carried out, methods for the expression and purification of full-length, active YoeBSa1 and 
for assaying its activity had not yet been developed, so these diagnostic experiments were not 
possible. As will be presented in the following chapter, it is now possible to obtain pure, active 
YoeBSa1, and a new YefMSa1 construct with a smaller 19-residue N-terminal (His)6-tag is able to 
inhibit YoeBSa1 in activity assays. Using this new YefMSa1 construct as a target for phage display 
with one of the Ph.D. libraries could enable the identification of a YefMSa1-specific peptide. 
However, the new YefMSa1 construct may also be partially or completely unfolded in the absence 
of YoeBSa1 and therefore unable to interact specifically with a phage-displayed peptide, resulting 
in selection for peptides similar to those obtained in biopans with (His)6YefMSa1. 
In contrast to YefMSa1, YoeBSa1 is predicted to be a well-folded protein. Now that pure, 
active YoeBSa1 can be readily obtained, it may be more fruitful to use YoeBSa1 as a target for 
future phage display experiments. To minimize selection for peptides that inhibit its activity, 
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YoeBSa1 could be pre-incubated with a short, uncleavable oligonucleotide that would bind in its 
active site and block peptide access. This approach may actually enable selection for peptides 
that enhance the activity of YoeBSa1 by stabilizing it in a catalytically competent conformation. 
Any peptides identified via phage display could then be evaluated for their ability to enhance 
YoeBSa1 RNase activity and to prevent or disrupt the interaction between YefMSa1 and YoeBSa1 
using the fluorometric assay described in the following chapter. 
 
2.4  CONCLUSIONS 
The prevalence, conservation, and transcription of the yefM-yoeBSa1 and yefM-yoeBSa2 
genes in clinical MRSA isolates suggests that these systems are excellent targets for assessing 
the tractability of artificial toxin activation as a novel antibacterial strategy. Although the 
identification of a peptide that binds to the antitoxin and prevents it from binding to the toxin is 
one possible strategy for direct toxin activation, failure to identify a peptide that specifically 
binds to YefMSa1 using phage display suggests that this approach may not be feasible for the 
YefM-YoeBSa1 TA system. Future efforts to discover a YoeBSa1 activator should therefore focus 
on peptides or small molecules that bind to YoeBSa1 and prevent its interaction with YefMSa1. 
 
2.5  MATERIALS & METHODS 
Bacterial Strains and Growth Conditions—MRSA clinical isolates were from a 
previously published collection (1). E. coli DH5α and BL21(DE3) (Invitrogen) were used for 
(His)6YefMSa1 cloning and expression, respectively. E. coli BL21 and BLT5615 (Novagen) were 
used for cloning, amplifying, and titering the 415 and 10 T7 phage libraries, respectively. 
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Kanamycin was used at 50 μg/ml for maintenance of pET-28a. Ampicillin was used at 50 μg/ml 
for propagation of BLT5615. 
Primers—All primers used for PCR, RT-PCR, and cloning were synthesized by 
Integrated DNA Technologies (IDT) and are listed in Table 2.2 at the end of this chapter. 
PCR Analysis—Total DNA was previously purified from a diverse collection of 78 
clinical isolates of MRSA (1). Primers YefM-YoeBSa1-F and YefM-YoeBSa1-R or YefM-
YoeBSa2-F and YefM-YoeBSa2-R were used to amplify the yefM-yoeBSa1 or yefM-yoeBSa2 loci, 
respectively, from the total DNA. PCR amplification was performed on a PTC-200 thermocycler 
(MJ Research) using previously described reaction conditions (1,19). PCR products were 
separated by electrophoresis on 1% agarose gels and stained with ethidium bromide.  
Sequence Analysis—Approximately 10% of the PCR products generated from PCR 
amplification of the yefM-yoeBSa1 and yefM-yoeBSa2 loci were submitted for DNA sequencing by 
the University of Illinois W. M. Keck Center for Comparative and Functional Genomics. 
Sequence data were analyzed using BioEdit 7.0.5.3 software. The sequences were aligned using 
CLUSTAL W (2) and used as query sequences to search the BLAST database to verify the 
identity of the PCR products and sequence homology to known genes (3). 
RT-PCR Analysis—MRSA isolates were streaked from glycerol stocks on Brain Heart 
Infusion (BHI) agar. Single colonies from freshly streaked plates were inoculated into 10 ml BHI 
medium and incubated aerobically at 37°C with shaking at 250 rpm overnight (14-16 h). 
Overnight cultures were diluted 1:100 in 10 ml BHI medium and incubated aerobically at 37°C 
with shaking at 250 rpm until the A600 reached 0.6 to 1.0. Logarithmically growing cultures were 
harvested by centrifugation at 3220 × g for 10 min at 4°C (Eppendorf Centrifuge 5810 R). Total 
RNA was purified using the FastRNA Pro Blue Kit (Qbiogene) according to the manufacturer’s 
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instructions with the modification that lysis was performed by vortexing resuspended cells at 
maximum speed for 5 × 1 min pulses at room temperature with 1-5 min recovery on ice between 
pulses. Isolated RNA was treated with DNase I (New England Biolabs (NEB)) and purified with 
reagents from the Total RNA Kit I (Omega Bio-Tek) according to the RNA Cleanup protocol 
from the RNeasy Mini Handbook (Qiagen). Purified total RNA (10 ng) was used in RT-PCR and 
in PCR with Platinum Taq DNA Polymerase (Invitrogen) to detect DNA contamination. RT-
PCR was performed with YefM-YoeBSa1-F and YefM-YoeBSa1-R or YefM-YoeBSa2-F and 
YefM-YoeBSa2-R primers using the Superscript III One-Step RT-PCR System with Platinum Taq 
(Invitrogen) as previously reported (19) with the following modifications: the annealing 
temperature was raised to 55°C, and the number of cycles was reduced to 35. PCR products were 
separated by electrophoresis on 1% agarose gels and stained with ethidium bromide. 
Construction of pET-28a-yefMSSa1—The yefMSa1 ORF was PCR-amplified from the total 
DNA of MRSA NRS3 (1) with primers YefMSa1-BamHI-F and YefMSa1-HindIII-R. The 
resulting PCR product was digested with BamHI and HindIII (NEB) and ligated into pET-28a 
(Novagen) digested with BamHI and HindIII to create pET-28a-yefMSa1.  
Expression and Purification of (His)6YefMSa1. pET-28a-yefMSa1 was introduced into E. 
coli BL21(DE3), and overnight cultures were grown in LB supplemented with 50 μg/ml 
kanamycin (LB/kanamycin) from single colonies picked from freshly streaked plates. Overnight 
cultures were diluted 1:100 in LB/kanamycin and grown at 37°C. When the A600 of the culture 
reached 0.4 to 0.6, protein expression was induced with 1 mM IPTG at 37°C for 4 h. Cultures 
were harvested by centrifugation at 6000 × g for 5 min at 4°C in a Sorvall SLA-3000 rotor. Cell 
pellets were frozen at -20°C, thawed on ice for 30 min, and resuspended in 10 ml cold lysis 
buffer (20 mM Tris, 500 mM NaCl, pH 7.9). Cells were lysed by sonication on ice at 40% 
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amplitude for 5 min with a 1 s pulse. The lysate was cleared by centrifugation at 35,000 × g for 
30 min at 4°C in a Sorvall SS-35 rotor. The clarified lysate was batch-loaded onto 1 ml 1:1 Ni-
NTA agarose (Qiagen) at 4°C for 30 min with inversion and poured into a 20 ml plastic column 
fitted with a bottom cap. Once the resin had settled and packed loosely in the bottom of the 
column, the cap was removed and the unbound material was allowed to flow through. The resin 
was washed with 10 ml cold lysis buffer followed by 20 ml cold wash buffer (20 mM Tris, 500 
mM NaCl, 60 mM imidazole, pH 7.9). Bound material was eluted with 10 ml cold elution buffer 
(20 mM Tris, 500 mM NaCl, 500 mM imidazole, pH 7.9). The eluted fraction was transferred to 
a 3.5K MWCO dialysis cassette (Pierce) and dialyzed against 1 L cold lysis buffer at 4°C 
overnight (14-16 h). The dialyzed protein was concentrated to ~1 ml using an Ultra-4 Centrifugal 
Filter Unit with Ultracel-3 membrane (Amicon) and stored at 4°C. Concentration was 
determined by BCA assay (Pierce) according to the manufacturer’s instructions. 
Secondary Structure Prediction—The amino acid sequence of (His)6YefMSa1 was 
uploaded into the online Jpred3 protein secondary structure prediction server 
(http://www.compbio.dundee.ac.uk/www-jpred) (9). Summary output is shown in Figure 2.6A. 
Circular Dichroism (CD)—CD spectra were acquired in the far-UV region using a J-715 
CD spectrometer (JASCO). A rectangular quartz cuvette with a total volume of 400 μl and a 
pathlength of 0.1 cm was employed for each spectrum. (His)6-YefMSa1 was diluted to 26.1 μM in 
optically clear phosphate buffer (20 mM sodium phosphate, pH 7.0) containing 0, 0.1, 0.2, 0.5, 
0.8, or 1.1% Tween-20. JASCO Spectra Manager software was used for data acquisition. CD 
spectra were obtained from 260 to 190 nm at a scan rate of 50 nm/s with a wavelength step of 1 
nm and a sensitivity of 100 mdeg for a total of 10 accumulations. Raw spectra were corrected by 
subtracting the average measured absorbance between 250 and 260 nm from the entire spectrum. 
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The corrected data was uploaded onto the online DICRHOWEB server 
(http://dichroweb.cryst.bbk.ac.uk) (8). The K2D algorithm optimized for evaluation of CD 
spectra in the 240 to 200 nm range (7) was used to predict secondary structural content. Spectra 
shown are K2D output. 
 Gel Filtration—Gel filtration was performed at 4°C on a HiLoad 16/60 Superdex 75 PG 
column using an AKTA FPLC system (GE Healthcare). Stock solutions of molecular weight 
standards were prepared by dissolving aprotinin (Sigma), carbonic anhydrase (Sigma), and 
bovine serum albumin Fraction V (Research Products International) at 20 mg/ml in lysis buffer. 
An aliquot of molecular weight standards (500 μl, 3 mg/ml each protein) or (His)6-YefMSa1 (300 
μl, 10 mg/ml) was 0.2 μm filtered and loaded onto the column, which was pre-equilibrated with 
lysis buffer. Separation was achieved using a flow rate of 0.5 ml/min. Elution was monitored by 
absorbance at 280 nm. UNICORN 5.01 software was used to identify peak elution volumes from 
elution profiles. The log molecular weight of the standards was plotted versus retention volume 
in Microsoft Excel, and linear regression was performed to obtain a calibration curve and 
estimate the molecular weight of (His)6-YefMSa1 from its retention volume. 
Construction of T7 Phage Libraries—T7 phage libraries were constructed using the 
T7Select 415-1 and 10-3 Cloning Kits (Novagen) according to the manufacturer’s instructions. 
Primer T7 Extend (100 μM) was annealed to the ssDNA oligonucleotides T7 X9 Insert, T7 CX7C 
Insert, T7 CX9C Insert, or T7 CX10C Insert (100 μM) in 10 mM Tris, 100 mM NaCl, pH 8.0, by 
denaturation at 95°C for 3 min and cooling to 25°C at a rate of 0.1°C/s. Primer extension was 
performed with the Large Klenow Fragment (NEB) at 37°C for 10 min to convert the ssDNA 
template to dsDNA. Double-stranded inserts were PCR-purified using the QIAquick PCR 
Purification Kit (Qiagen) according to the manufacturer’s instructions and sequentially digested 
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with EcoRI and HindIII (NEB) with PCR purification after each digestion step. Doubly-digested 
inserts were ligated into the T7Select 415-1b or 10-3b vector arms (Novagen) using T4 DNA 
Ligase (NEB) at 16°C for 14-16 h. Ligation reactions (5 μl) were added directly to thawed 
aliquots of T7 Packaging Extract (25 μl, Novagen) and incubated at 25°C for 2 h. Packaging was 
quenched by the addition of sterile LB medium (270 μl). Quenched packaging reactions were 
stored at 4°C until the number of primary recombinants was determined by plaque assay. 
Libraries were amplified by infecting the appropriate E. coli host strain (BL21 for 415 libraries 
and BLT5615 for 10 libraries) at a multiplicity of infection of 1 × 10
3
, or 10
3
 cells per pfu. The 
infected host cells were grown aerobically at 37°C with shaking at 250 rpm until lysis was 
observed. Lysed cultures were clarified by centrifugation at 3220 × g, and the clarified lysate 
was stored at 4°C and titered by plaque assay. 
Plaque Assay—E. coli BL21 or BLT5615 were streaked from glycerol stocks on LB or 
LB/ampicillin agar, respectively. Single colonies from freshly streaked plates were inoculated 
into 10 ml LB or LB/ampicillin medium and incubated aerobically at 37°C with shaking at 250 
rpm overnight (14-16 h). Overnight cultures were diluted 1:100 in LB or LB/ampicillin medium 
and incubated aerobically at 37°C with shaking at 250 rpm until the A600 reached ~1.0. Serial 
tenfold dilutions of phage were prepared in sterile LB medium, and 100 μl aliquots were mixed 
with the appropriate strain of logarithmically growing E. coli in molten top agar and spread on 
LB agar plates. Titers were determined by counting the number of plaques on plates containing 
between 10 and 300 well-spaced plaques. 
Plaque PCR—Well-spaced plaques were selected at random for sequence analysis. 
Plaques were scraped using pipette tips and phage were resuspended in 100 μl 10 mM EDTA, 
pH 8.0, by pipetting up and down several times. Tubes were vortexed briefly, incubated at 65°C 
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for 10 min to lyse the phage, and centrifuged at 14,000 × g for 3 min to clarify the phage lysate. 
Clarified lysate (2 μl) was used as template for PCR with primers T7SelectUP 21346 and 
T7SelectDN 21696. PCR amplification was carried out in a PTC-200 thermocycler (MJ 
Research) with an initial denaturation step (94°C, 3 min); 35 cycles of denaturation (94°C, 50 s), 
annealing (60°C, 1 min), and extension (72°C, 1 min); and a final extension step (72°C, 6 min). 
PCR reactions were PCR-purified and submitted for DNA sequencing. Sequence logos were 
created by uploading peptide sequences into the online WebLogo server 
(http://weblogo.berkeley.edu/logo.cgi) (20). 
Biopans 1-4—For all rounds of Biopans 1-4, immobilization of (His)6YefMSa1 was 
carried out by incubating (His)6YefMSa1 with Ni-NTA resin in Tris-buffered saline (TBS) at 4 °C 
for 2 h. For round 1, (His)6YefMSa1 (100 μl) was immobilized on Ni-NTA agarose (20 μl 50% 
slurry, Qiagen). For round 2, (His)6YefMSa1 (50 μl, 1 mg/ml) was immobilized on MagneHis Ni-
Particles (5 μl suspension, Promega). For rounds 3 and 4, (His)6YefMSa1 was immobilized as in 
rounds 1 and 2, respectively, but the volumes of (His)6YefMSa1 and solid support were reduced 
by a factor of two. Following immobilization, the resin was collected by centrifugation, and the 
supernatant was removed for SDS-PAGE analysis. The resin was then washed three times with 
100 μl TBS, blocked with 200 μl 5% BSA (rounds 1 and 3) or 200 μl 5% casein (rounds 2 and 4) 
in TBS at room temperature for 1 h, and washed three times with 200 μl TBS. Identical methods 
were used for –YefM biopans except that (His)6YefMSa1 was replaced by TBS. 
For round 1 of Biopans 1 and 3, the 415-X9 library was diluted to a multiplicity of 100 
(100 pfu of each primary recombinant) in 100 μl 0.2% TBST (TBS containing 0.2% Tween-20) 
and incubated with resin ±(His)6YefMSa1 at room temperature for 25 min. The resin was then 
collected by centrifugation, the supernatant was removed, and the resin was washed five times 
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with 200 μl 0.2% TBST to remove non-specifically bound phage. In rounds 2, 3, and 4, the 
incubation time was reduced to 22, 18, and 15 min, and the number of washes was increased to 
6, 7, and 8, respectively. After washing, bound phage were eluted by incubation with 200 μl 
elution buffer (Biopan 1) or 200 μl TBS containing 1% SDS (Biopan 3) at room temperature for 
20 min. The resin was collected by centrifugation, and the supernatant was removed and 
amplified by infection of E. coli BL21. 
Prior to round 1 of Biopans 2 and 4, Ni-NTA agarose (100 μl 50% slurry) was blocked 
with 1 ml 5% BSA in TBS at room temperature for 1 h. The resin was then washed three times 
with 1 ml TBS, and the 415-X9 library was diluted to a multiplicity of 500 in 500 μl 0.2% TBST 
and incubated with the blocked resin at room temperature for 25 min. The supernatant was 
removed and 100 μl was used as input for round 1 of Biopans 2 and 4 ±(His)6YefMSa1. The 
remainder of rounds 1-4 of Biopans 2 and 4 were carried out as described for Biopans 1 and 3. 
A plaque assay was performed on amplified eluted phage from round 4. Fifteen plaques 
from +YefM biopans and five (Biopans 1 and 2) or ten (Biopans 3 and 4) plaques from –YefM 
biopans were selected, the DNA sequences encoding the displayed peptides were PCR-
amplified, and the PCR products were subjected to DNA sequencing. 
Biopans 5 and 6—A preclear was included prior to each round of Biopans 5 and 6. 
MagneHis Ni-Particles (50 μl suspension) were blocked with 1 ml 5% skim milk (rounds 1 and 
3) or 1 ml 5% BSA (rounds 2 and 4) in 0.2% TBST at room temperature for 1 h. The resin was 
collected by centrifugation, the supernatant was removed, and the resin was washed five times 
with 2 ml 0.2% TBST. For round 1, the 415-X9 library (Biopan 5) or the pooled 415-CX7C, -
CX9C, and -CX10C libraries (Biopan 6) were diluted to a multiplicity of 100 in 200 μl 0.2% 
TBST and incubated with the blocked resin at room temperature for 30 min. The supernatant was 
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removed and used as input for biopanning. For rounds 2, 3, and 4, the same volume of amplified 
eluted phage from the previous round was diluted in 0.5, 0.8, and 1.1% TBST, respectively, and 
precleared using the same method. 
Immobilization of (His)6YefMSa1 was carried out by incubating (His)6YefMSa1 (1 mg/ml) 
or TBS with MagneHis Ni-Particles at room temperature for 2 h. For round 1, 100 μl 
(His)6YefMSa1 or TBS was added to a 10 μl suspension of MagneHis Ni-Particles. Volumes of 
(His)6YefMSa1, TBS, and resin were reduced by a factor of two for each subsequent round. The 
resin was collected by centrifugation, and the supernatant was removed for SDS-PAGE analysis. 
The resin was then washed five times with 500 μl TBS, blocked with 200 μl 5% skim milk 
(rounds 1 and 3) or 200 μl 5% BSA (rounds 2 and 4) in 0.2% TBST at room temperature for 1 h, 
and washed five times with 500 μl 0.2% TBST. Precleared phage (~200 μl) were then incubated 
with blocked resin ±(His)6YefMSa1 at room temperature for 30, 25, 20, and 15 min in rounds 1, 2, 
3, and 4, respectively. The resin was collected by centrifugation, the supernatant was removed, 
and the resin was washed 5, 6, 7, or 8 times with 500 μl 0.2, 0.5, 0.8, or 1.1% TBST with mixing 
for 2, 5, 8, or 11 min per wash in rounds 1, 2, 3, or 4, respectively. Bound phage were eluted by 
incubation with 200 μl 0.2% TBST containing 1% SDS at room temperature for 40 min. The 
resin was collected by centrifugation, and the supernatant was removed and amplified by 
infection of E. coli BL21. A plaque assay was performed on amplified eluted phage from round 
4. Fifteen plaques from ±YefM biopans were selected, the DNA sequences encoding the 
displayed peptides were PCR-amplified, and the PCR products were subjected to DNA 
sequencing. 
Biopans 7 and 8—Nunc Maxisorp plates were used for immobilization of (His)6YefMSa1 
in Biopans 7 and 8. Wells were washed five times with MilliQ H2O, and 100 μl (His)6YefMSa1 
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(10 μg/ml in TBS) or TBS was added and allowed to adsorb overnight (16 h) at 4°C. Wells were 
emptied, washed three times with 200 μl TBS, blocked with 200 μl 5% skim milk (rounds 1, 3, 
and 5) or 200 μl 5% BSA (rounds 2 and 4) in TBS for 1 h at room temperature, emptied, and 
washed five times with 300 μl TBS. For round 1, the 415-X9, -CX7C, -CX9C, and -CX10C 
libraries (Biopan 7) or the 10-X9, -CX7C, -CX9C, and -CX10C libraries (Biopan 8) were diluted 
to a multiplicity of 100 in 200 μl 0.2% TBST and incubated in ±(His)6YefMSa1 wells at room 
temperature for 1 h. For rounds 2-5, the same volume of amplified eluted phage from the 
previous round was diluted in 0.2% TBST and incubated in ±(His)6YefMSa1 wells at room 
temperature for 1 h. Wells were then emptied and washed 5, 10, 15, 20, or 25 times with 200 μl 
0.2% TBST in rounds 1, 2, 3, 4, and 5, respectively. Bound phage were eluted by addition of 200 
μl 0.2% TBST containing 1% SDS and incubation at room temperature for 40 min. Eluted phage 
were removed and amplified by infection of E. coli BL21 (Biopan 7) or BLT5615 (Biopan 8). A 
plaque assay was performed using phage amplified from round 5. Fifteen plaques from ±YefM 
biopans were selected, the DNA sequences encoding the displayed peptides were PCR-
amplified, and the PCR products were subjected to DNA sequencing. 
Biopans 9 and 10—Solution-phase biopanning methodology was employed in Biopans 9 
and 10. For round 1, MagneHis Ni-Particles (30 μl suspension) were washed once with 1 ml 
0.2% TBST, blocked with 1 ml 5% BSA in TBS at 4°C for 1 h, and washed four times with 1 ml 
0.2% TBST. (His)6YefMSa1 (100 nM) or an equivalent volume of TBS was incubated with the 
10-X9 library (Biopan 9) or the pooled 10-CX7C, -CX9C, and -CX10C libraries (Biopan 10) at a 
multiplicity of 100 in 400 μl 0.2% TBST at room temperature for 30 min. Imidazole was added 
to a final concentration of 40 mM, and the mixture was incubated with the blocked resin at room 
temperature for 15 min. The resin was washed ten times with 1 ml 0.2% TBST, and bound phage 
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were eluted with 400 μl 0.2% TBST containing 1% SDS at room temperature for 30 min and 
amplified by infection of E. coli BLT5615. A similar method was employed for rounds 3 and 5 
with the modifications that the resin volume was reduced to 20 and 10 μl, incubation of 
(His)6YefMSa1 with phage was reduced to 20 and 15 min, and incubation of (His)6YefMSa1 with 
phage and washes were performed using 0.8 and 1.1% TBST, respectively. 
For round 2, Ni-NTA agarose (25 μl 50% slurry) was washed once with 1 ml 0.5% 
TBST, blocked with 1 ml 5% skim milk in TBS at 4°C for 1 h, and washed four times with 1 ml 
0.5% TBST. Amplified eluted phage from round 1 were precleared prior to incubation with 
(His)6YefMSa1. Ni-NTA agarose (50 μl 50% slurry) was washed once with 1 ml 0.5% TBST, 
blocked with 1 ml 5% skim milk in TBS at 4°C for 1 h, and washed four times with 1 ml 0.5% 
TBST. The blocked Ni-NTA agarose was incubated with amplified eluted phage from the 
previous round in 400 μl 0.5% TBST at room temperature for 25 min. The resin was then 
collected by centrifugation, and the supernatant was removed and incubated with (His)6YefMSa1 
(100 nM) or an equivalent volume of TBS at room temperature for 25 min. Imidazole was added 
to a final concentration of 40 mM, and the mixture was incubated with the blocked resin at room 
temperature for 15 min. The resin was washed ten times with 1 ml 0.5% TBST, and bound phage 
were eluted and amplified as described for round 1. A similar method was employed for rounds 4 
and 6 with the modifications that the resin volume was increased to 50 μl, incubation of 
(His)6YefMSa1 with phage was reduced to 15 min, and incubation of (His)6YefMSa1 with phage 
and washes were performed with 1.1% TBST. Plaque assays were performed using phage 
amplified from rounds 4 and 6. Fifteen plaques were selected from each round, the DNA 
sequences encoding the displayed peptides were PCR-amplified, and the PCR products were 
subjected to DNA sequencing. 
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Biopans 11 and 12—Solution-phase biopanning methodology was employed in Biopans 
11 and 12. All incubation and wash steps were performed using TBS (Biopan 11) or 0.2% TBST 
(Biopan 12). For round 1, MagneHis Ni-Particles (50 μl suspension) were washed once with 1 
ml TBS/T. (His)6YefMSa1 (1 μM) or an equivalent volume of TBS was incubated with the 10-X9 
library at a multiplicity of 100 in 200 μl TBS/T at room temperature for 30 min. Imidazole was 
added to a final concentration of 40 mM, and the (His)6YefMSa1/phage/imidazole mixture was 
added to the washed resin and incubated at room temperature for 15 min. The resin was then 
washed ten times with 1 ml TBS/T, and bound phage were eluted by incubation with 200 μl 
0.2% TBST containing 1% SDS at room temperature for 30 min and amplified by infection of E. 
coli BLT5615. 
A preclear was included prior to rounds 2-4. MagneHis Ni-particles (50 μl suspension) 
were washed with 1 ml TBS/T and incubated with amplified eluted phage from the previous 
round in 200 μl TBS/T at room temperature for 30 min. The resin was then collected by 
centrifugation, and the supernatant was removed and used for biopanning as described for round 
1. Plaque assays were performed using phage amplified from round 4. Fifteen plaques from 
±YefM biopans were selected, the DNA sequences encoding the displayed peptides were PCR-
amplified, and the PCR products were subjected to DNA sequencing. 
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2.6  TABLES AND FIGURES 
Table 2.1 Primers used in this study. 
Primer Sequence 
T7 Extend 5'-CGG CCC AAG CTT TTA-3' 
T7 X9 Insert 5'-GAT CCG AAT TCC GAA (NNK)9 TAA AAG CTT GGG CCG-3' 
T7 CX7C Insert 5'-GAT CCG AAT TCC GAA TGT (NNK)7 TGT TAA AAG CTT GGG CCG-3' 
T7 CX9C Insert 5'-GAT CCG AAT TCC GAA TGT (NNK)9 TGT TAA AAG CTT GGG CCG-3' 
T7 CX10C Insert 5'-GAT CCG AAT TCC GAA TGT (NNK)10 TGT TAA AAG CTT GGG CCG-3' 
T7SelectUP 21346 5'-GTT AAG CTG CGT GAC TTG GC-3' 
T7SelectDN 21696 5'-GTT AGC GTC ACC TTC CAG CG-3' 
YefMSa1 BamHI-F 5'-AAA AAA GGA TCC ATG ATT ATT AAA AAT TAT TCA TAC GCT CG-3' 
YefMSa1 HindIII-R 5'-AAA AAA AAG CTT ATA CAT CTA TAT CTT TCG TTA TAG TTT TC-3' 
YefM-YoeBSa1-F 5'-CGC TCG ACA GAA TTT AAA GG-3' 
YefM-YoeBSa1-R 5'-CCT TCC AAT GCA CCA TTT C-3' 
YefM-YoeBSa2-F 5'-GGT ATA GAC GAC CCT GTG CTG-3' 
YefM-YoeBSa2-R 5'-GCC CTA CAG AAG CGA GAA AAG-3' 
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Table 2.2 PCR results with MRSA total genomic DNA. Hospital 1 is Carle Foundation Hospital (Urbana, IL), 
Hospital 2 is Delnor Community Hospital (Geneva, IL), Hospital 3 is Memorial Medical Center (Springfield, IL), 
and NARSA is Network on Antimicrobial Resistance in Staphylococcus aureus. 
 
  Toxin-Antitoxin System     Toxin-Antitoxin System 
Isolate yefM-yoeB
Sa1
 yefM-yoeB
Sa2
   Isolate yefM-yoeB
Sa1
 yefM-yoeB
Sa2
 
Hospital 1 
  
  S5 (+) (+) 
C1 (+) (+)   S6 (+) (+) 
C2 (+) (+)   S7 (+) (+) 
C3 (+) (+)   S8 (+) (+) 
C4 (+) (+)   S9 (+) (+) 
C5 (+) (+)   S10 (+) (+) 
C6 (+) (+)   S11 (+) (+) 
C7 (+) (+)   S12 (+) (+) 
C8 (+) (+)   S13 (+) (+) 
C9 (+) (+)   S14 (+) (+) 
C10 (+) (+)   S15 (+) (+) 
C11 (+) (+)   S16 (+) (+) 
C12 (+) (+)   S17 (+) (+) 
C13 (+) (+)   S18 (+) (+) 
C14 (+) (+)   S19 (+) (+) 
C15 (+) (+)   S20 (+) (+) 
C16 (+) (+)   S21 (+) (+) 
C17 (+) (+)   S22 (+) (+) 
C18 (+) (+)   S23 (+) (+) 
C19 (+) (+)   S24 (+) (+) 
C21 (+) (+)   S25 (+) (+) 
C26 (+) (+)   S26 (+) (+) 
Hospital 2 
  
  NARSA     
G1 (+) (+)   NRS3 (+) (+) 
G2 (+) (+)   NRS4 (+) (+) 
G3 (+) (+)   NRS17 (+) (+) 
G4 (+) (+)   NRS18 (+) (+) 
G5 (+) (+)   NRS21 (+) (+) 
G6 (+) (+)   NRS22 (+) (+) 
G8 (+) (+)   NRS23 (+) (+) 
G9 (+) (+)   NRS24 (+) (+) 
G10 (+) (+)   NRS26 (+) (+) 
G11 (+) (+)   NRS27 (‒) (‒) 
G12 (+) (+)   NRS28 (+) (+) 
G13 (+) (+)   NRS29 (+) (+) 
G14 (+) (+)   NRS51 (+) (+) 
Hospital 3 
  
  NRS68 (+) (+) 
S1 (+) (+)   NRS73 (+) (+) 
S2 (+) (+)   NRS74 (+) (+) 
S3 (+) (+)   NRS76 (+) (+) 
S4 (+) (+)   NRS382 (+) (+) 
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Table 2.3 Diversities of T7 phage libraries constructed in this study. 
 
Copy Number Peptide Sequence Primary Recombinants Possible Diversity % Possible Diversity 
10 X9
 3.0 × 10
6
 20
9
 = 5.1 × 10
11
 5.9 × 10
-4
 
10 CX7
C 2.9 × 10
6
 20
7
 = 1.3 × 10
9
 2.3 × 10
-1
 
10 CX9
C 1.1 × 10
6
 20
9
 = 5.1 × 10
11
 2.1 × 10
-4
 
10 CX10
C 1.0 × 10
6
 20
10
 = 1.0 × 10
13
 9.8 × 10
-6
 
415 X9
 2.0 × 10
7
 20
9
 = 5.1 × 10
11
 3.9 × 10
-3
 
415 CX7
C 1.8 × 10
6
 20
7
 = 1.3 × 10
9
 1.4 × 10
-1
 
415 CX9
C 2.9 × 10
6
 20
9
 = 5.1 × 10
11
 5.7 × 10
-4
 
415 CX10
C 6.4 × 10
6
 20
10
 = 1.0 × 10
13
 6.3 × 10
-5
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Figure 2.17 Clustal W multiple sequence alignment of yefM-yoeBSa1 PCR products from 9 of the 77 clinical MRSA 
strains found to contain yefM-yoeBSa1 by PCR. Bases highlighted in bold on the reference sequence from the S. 
aureus COL genome indicate the location of the primers used to detect the yefM-yoeBSa1 sequence. 
 
COL_MBSa1       TTAATAATGGTATTTACATGATGCTATTTTTATATGATTGTCATCTACTGTATAAACCAA 
C2              ------------------------------------------------------------ 
C6              ------------------------------------------------------------ 
G1              ------------------------------------------------------------ 
G8              ------------------------------------------------------------ 
S10             ------------------------------------------------------------ 
S22             ------------------------------------------------------------ 
NRS28           ------------------------------------------------------------ 
NRS51           ------------------------------------------------------------ 
NRS68           ------------------------------------------------------------ 
 
 
COL_MBSa1       TCTATGTTCGTGATTGATACGTCTACTATAATACCCAGTCAGATTCGATTTTAACTTTTC 
C2              ------------------------------------------------------------ 
C6              ------------------------------------------------------------ 
G1              ------------------------------------------------------------ 
G8              ------------------------------------------------------------ 
S10             ------------------------------------------------------------ 
S22             ------------------------------------------------------------ 
NRS28           ------------------------------------------------------------ 
NRS51           ------------------------------------------------------------ 
NRS68           ------------------------------------------------------------ 
 
 
COL_MBSa1       AGGCTTACCTATACCTTCCAATGCACCATTTCTGTCAATACTTTTAAGTAACTCATTAAT 
C2              -------------CCTTCCAATGCACCATTTCTGTCAATACTTTTAAGTAACTCATTAAT 
C6              -------------CCTTCCAATGCACCATTTCTGTCAATACTTTTAAGTAACTCATTAAT 
G1              -------------CCTTCCAATGCACCATTTCTGTCAATACTTTTAAGTAACTCATTAAT 
G8              -------------CCTTCCAATGCACCATTTCTGTCAATACTTTTAAGTAACTCATTAAT 
S10             -------------CCTTCCAATGCACCATTTCTGTCAATACTTTTAAGTAACTCATTAAT 
S22             -------------CCTTCCAATGCACCATTTCTGTCAATACTTTTAAGTAACTCATTAAT 
NRS28           -------------CCTTCCAATGCACCATTTCTGTCAATACTTTTAAGTAACTCATTAAT 
NRS51           -------------CCTTCCAATGCACCATTTCTGTCAATACTTTTAAGTAACTCATTAAT 
NRS68           -------------CCTTCCAATGCACCATTTCTGTCAATACTTTTAAGTAACTCATTAAT 
                             *********************************************** 
 
COL_MBSa1       CTTCTTCACCATTTTTTT-ATCGTTCTGCTGAAAATACTTATAATCTTCAAAGGCTTGAG 
C2              CTTCTTCACCATTTTTTT-ATCGTTCTGCTGAAAATACTTATAATCTTCAAAGGCTTGAG 
C6              CTTCTTCACCATTTTTTT-ATTGTTCTGCTGAAAATACTTATAATCTTCAAAGGCTTGAG 
G1              CTTCTTCACCATTTTTTTTATTGTTCTGCTGAAAATACTTATAATCTTCAAAGGCTTGAG 
G8              CTTCTTCACCATTTTTTT-ATCGTTCTGCTGAAAATACTTATAATCTTCAAAGGCTTGAG 
S10             CTTCTTCACCATTTTTTT-ATTGTTCTGCTGAAAATACTTATAATCTTCAAAGGCTTGAG 
S22             CTTCTTCACCATTTTTTT-ATCGTTCTGCTGAAAATACTTATAATCTTCAAAGGCTTGAG 
NRS28           CTTCTTCACCATTTTTTT-ATCGTTCTGCTGAAAATACTTATAATCTTCAAAGGCTTGAG 
NRS51           CTTCTTCACCATTTTTTT-ATCGTTCTGCTGAAAATACTTATAATCTTCAAAGGCTTGAG 
NRS68           CTTCTTCACCATTTTTTT-ATTGTTCTGCTGAAAATACTTATAATCTTCAAAGGCTTGAG 
                ****************** ** ************************************** 
 
COL_MBSa1       GCGAAAACGTAATATTTAACCTAGCCATTATACATCTATATCTTTCGTTATAGTTTTCCC 
C2              GCGAAAACGTAATATTTAACCTAGCCATTATACATCTATATCTTTCGTTATAGTTTTTCC 
C6              GCGAAAACGTAATATTTAACCTAGCCATTATACATCTATATCTTTCGTTATAGTTTTCCC 
G1              GCGAAAACGTAATATTTAACCTAGCCATTATACATCTATATCTTTCGTTATAGTTTTCCC 
G8              GCGAAAACGTAATATTTAACCTAGCCATTATACATCTATATCTTTCGTTATAGTTTTCCC 
S10             GCGAAAACGTAATATTTAACCTAGCCATTATACATCTATATCTTTCGTTATAGTTTTCCC 
S22             GCGAAAACGTAATATTTAACCTAGCCATTATACATCTATATCTTTCGTTATAGTTTTCCC 
NRS28           GCGAAAACGTAATATTTAACCTAGCCATTATACATCTATATCTTTCGTTATAGTTTTCCC 
NRS51           GCGAAAACGTAATATTTAACCTAGCCATTATACATCTATATCTTTCGTTATAGTTTTCCC 
NRS68           GCGAAAACGTAATATTTAACCTAGCCATTATACATCTATATCTTTCGTTATAGTTTTCCC 
                ********************************************************* ** 
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Figure 2.17, continued  
 
COL_MBSa1       ACGTTCTAGATCTGCAATTGATTGAGCTAAGTGTTCAGCATTATTTGGGTTCTGTTGGAG 
C2              ACGTTCTAGATCTGCAATTGATTGAGCTAAGTGTTCAGCATTATTTGGATTCTGTTGGAG 
C6              ACGTTCTAGATCTGCAATTGATTGAGCTAAGTGTTCAGCATTATTTGGGTTCTGTTGGAG 
G1              ACGTTCTAGATCTGCAATTGATTGAGCTAAGTGTTCAGCATTATTTGGGTTCTGTTGGAG 
G8              ACGTTCTAGATCTGCAATTGATTGAGCTAAGTGTTCAGCATTATTTGGGTTCTGTTGGAG 
S10             ACGTTCTAGATCTGCAATTGATTGAGCTAAGTGTTCAGCATTATTTGGGTTCTGTTGGAG 
S22             ACGTTCTAGATCTGCAATTGATTGAGCTAAGTGTTCAGCATTATTTGGGTTCTGTTGGAG 
NRS28           ACGTTCTAGATCTGCAATTGATTGAGCTAAGTGTTCAGCATTATTTGGGTTCTGTTGGAG 
NRS51           ACGTTCTAGATCTGCAATTGATTGAGCTAAGTGTTCAGCATTATTTGGGTTCTGTTGGAG 
NRS68           ACGTTCTAGATCTGCAATTGATTGAGCTAAGTGTTCAGCATTATTTGGGTTCTGTTGGAG 
                ************************************************ *********** 
 
COL_MBSa1       GTAAAGTGTTTCCATCATGGAGTTATAATCTGATTCTGACATGATTACTACGTTTTTATC 
C2              GTAAAGTGTTTCCATCATGGAGTTATAATCTGATTCTGACATGATTACTACGTTTTTATC 
C6              GTAAAGTGTTTCCATCATGGAGTTATAATCTGATTCTGACATGATTACTACGTTTTTATC 
G1              GTAAAGTGTTTCCATCATGGAGTTATAATCTGATTCTGACATGATTACTACGTTTTTATC 
S10             GTAAAGTGTTTCCATCATGGAGTTATAATCTGATTCTGACATGATTACTACGTTTTTATC 
S22             GTAAAGTGTTTCCATCATGGAGTTATAATCTGATTCTGACATGATTACTACGTTTTTATC 
NRS28           GTAAAGTGTTTCCATCATGGAGTTATAATCTGATTCTGACATGATTACTACGTTTTTATC 
NRS51           GTAAAGTGTTTCCATCATGGAGTTATAATCTGATTCTGACATGATTACTACGTTTTTATC 
NRS68           GTAAAGTGTTTCCATCATGGAGTTATAATCTGATTCTGACATGATTACTACGTTTTTATC 
                ************************************************************ 
 
COL_MBSa1       ATCAGTAGATGTTACAGTTACCATATCACTATCATCATTTACTTTTGTCATAAGTGCCTT 
C2              ATCAGTAGAGGTTACAGTTACCATATCACTATCATCATTTACTTTTGTCATAAGTGCCTT 
C6              ATCAGTAGATGTTACAGTTACCATATCACTATCATCATTTACTTTTGTCATAAGTGCCTT 
G1              ATCAGTAGATGTTACAGTTACCATATCACTATCATCATTTACTTTTGTCATAAGTGCCTT 
S10             ATAAAGTGTTTCCATCATGGAGTTATAATCTGATTCTGACATGATTACTACGTTTTTATC 
S22             ATAAAGTGTTTCCATCATGGAGTTATAATCTGATTCTGACATGATTACTACGTTTTTATC 
NRS28           ATCAGTAGATGTTACAGTTACCATATCACTATCATCATTTACTTTTGTCATAAGTGCCTT 
NRS51           ATCAGTAGATGTTACAGTTACCATATCACTATCATCATTTACTTTTGTCATAAGTGCCTT 
NRS68           ATCAGTAGATGTTACAGTTACCATATCACTATCATCATTTACTTTTGTCATAAGTGCCTT 
                ********* ************************************************** 
 
COL_MBSa1       TAAATTCTGTCGAGCGTATGAATAATTTTTAATAATCAT     Sequence Identity 
C2              TAAATTCTGTCGAGCG----------------------- 99% 
C6              TAAATTCTGTCGAGCG----------------------- 99% 
G1              TAAATTCTGTCGAGCG----------------------- 99% 
G8              TAAATTCTGTCGAGCG-----------------------     100% 
S10             TAAATTCTGTCGAGCG-----------------------     99% 
S22             TAAATTCTGTCGAGCG-----------------------     100% 
NRS28           TAAATTCTGTCGAGCG----------------------- 100% 
NRS51           TAAATTCTGTCGAGCG----------------------- 100% 
NRS68           TAAATTCTGTCGAGCG----------------------- 99% 
                ****************                        
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Figure 2.18 Clustal W multiple sequence alignment of yefM-yoeBSa2 PCR products from 9 of the 77 clinical MRSA 
strains found to contain yefM-yoeBSa2 by PCR. Bases highlighted in bold on the reference sequence from the S. 
aureus COL genome indicate the location of the primers used to detect the yefM-yoeBSa2 sequence. 
 
COL_MBSa2       TTAATCATAATGTGACCATGCCGATAGTATTAATACTTCTTTATTTCGATCATCTACGGT 
C6              ---------------------------------------------------------GGT 
C18             ---------------------------------------------------------GGT 
G5              ---------------------------------------------------------GGT 
G10             ---------------------------------------------------------GGT 
G14             ---------------------------------------------------------GGT 
S14             ---------------------------------------------------------GGT 
S15             ---------------------------------------------------------GGT 
NRS28           ---------------------------------------------------------GGT 
NRS76           ---------------------------------------------------------GGT 
                                                                         *** 
 
COL_MBSa2       ATAGACGACCCTGTGCTGATGGTTAATTCTTCTTGAATATCGCTCTAAATATTTAGGCTC 
C6              ATAGACGACCCTGTGCTGATGGTTAATTCTTCTTGAATATCGCTCTAAATATTTAGGCTC 
C18             ATAGACGACCCTGTGCTGATGGTTAATTCTTCTTGAATATCGCTCTAAATATTTAGGCTC 
G5              ATAGACGACCCTGTGCTGATGGTTAATTCTTCTTGAATATCGCTCTAAATATTTAGGCTC 
G10             ATAGACGACCCTGTGCTGATGGTTAATTCTTCTTGAATATCGCTCTAAATATTTAGGCTC 
G14             ATAGACGACCCTGTGCTGATGGTTAATTCTTCTTGAATATCGCTCTAAATATTTAGGCTC 
S14             ATAGACGACCCTGTGCTGATGGTTAATTCTTCTTGAATATCGCTCTAAATATTTAGGCTC 
S15             ATAGACGACCCTGTGCTGATGGTTAATTCTTCTTGAATATCGCTCTAAATATTTAGGCTC 
NRS28           ATAGACGACCCTGTGCTGATGGTTAATTCTTCTTGAATATCGCTCTAAATATTTAGGCTC 
NRS76           ATAGACGACCCTGTGCTGATGGTTAATTCTTCTTGAATATCGCTCTAAATATTTAGGCTC 
                ************************************************************ 
 
COL_MBSa2       TAATTTTTCAAAAGATTGTGTTATTTTATACGGATCATTTTTTAAAGTCTCAACAATTTC 
C6              TAATTTTTCAAAAGATTGTGTTATTTTATACGGATCATTTTTTAAAGTCTCAACAATTTC 
C18             TAATTTTTCAAAAGATTGTGTTATTTTATACGGATCATTTTTTAAAGTCTCAACAATTTC 
G5              TAATTTTTCAAAAGATTGTGTTATTTTATACGGATCATTTTTTAAAGTCTCAACAATTTC 
G10             TAATTTTTCAAAAGATTGTGTTATTTTATACGGATCATTTTTTAAAGTCTCAACAATTTC 
G14             TAATTTTTCAAAAGATTGTGTTATTTTATACGGATCATTTTTTAAAGTCTCAACAATTTC 
S14             TAATTTTTCAAAAGATTGTGTTATTTTATACGGATCATTTTTTAAAGTCTCAACAATTTC 
S15             TAATTTTTCAAAAGATTGTGTTATTTTATACGGATCATTTTTTAAAGTCTCAACAATTTC 
NRS28           TAATTTTTCAAAAGATTGTGTTATTTTATACGGATCATTTTTTAAAGTCTCAACAATTTC 
NRS76           TAATTTTTCAAAAGATTGTGTTATTTTATACGGATCATTTTTTAAAGTCTCAACAATTTC 
                ************************************************************ 
 
COL_MBSa2       TAAAAATGACTTCTTTAAATAAGAATGTTTTATTTTCTTTAAATCTGATTTCGCTGAATT 
C6              TAAAAATGACTTCTTTAAATAAGAATGTTTTATTTTCCTTAAATCTGATTTCGCTGAATT 
C18             TAAAAATGACTTCTTTAAATAAGAATGTTTTATTTTCTTTAAATCTGATTTCGCTGAATT 
G5              TAAAAATGACTTCTTTAAATAAGAATGTTTTATTTTCCTTAAATCTGATTTCGCTGAATT 
G10             TAAAAATGACTTCTTTAAATAAGAATGTTTTATTTTCCTTAAATCTGATTTCGCTGAATT 
G14             TAAAAATGACTTCTTTAAATAAGAATGTTTTATTTTCTTTAAATCTGATTTCGCTGAATT 
S14             TAAAAATGACTTCTTTAAATAAGAATGTTTTATTTTCCTTAAATCTGATTTCGCTGAATT 
S15             TAAAAATGACTTCTTTAAATAAGAATGTTTTATTTTCCTTAAATCTGATTTCGCTGAATT 
NRS28           TAAAAATGACTTCTTTAAATAAGAATGTTTTATTTTCTTTAAATCTGATTTCGCTGAATT 
NRS76           TAAAAATGACTTCTTTAAATAAGAATGTTTTATTTTCCTTAAATCTGATTTCGCTGAATT 
                ************************************* ********************** 
 
COL_MBSa2       TTTAATCTTAACCGTGTAATTGCTCATTAAAGATTATCCCAATCAATATCATCTATATTT 
C6              TTTAATCTTAACCGTGTAATTGCTCATTAAAGATTATCCCAATCAATATCATCTATATTT 
C18             TTTAATCTTAACCGTGTAATTGCTCATTAAAGATTATCCCAATCAATATCATCTATATTT 
G5              TTTAATCTTAACCGTGTAATTGCTCATTAAAGATTATCCCAATCAATATCATCTATATTT 
G10             TTTAATCTTAACCGTGTAATTGCTCATTAAAGATTATCCCAATCAATATCATCTATATTT 
G14             TTTAATCTTAACCGTGTAATTGCTCATTAAAGATTATCCCAATCAATATCATCTATATTT 
S14             TTTAATCTTAACCGTGTAATTGCTCATTAAAGATTATCCCAATCAATATCATCTATATTT 
S15             TTTAATCTTAACCGTGTAATTGCTCATTAAAGATTATCCCAATCAATATCATCTATATTT 
NRS28           TTTAATCTTAACCGTGTAATTGCTCATTAAAGATTATCCCAATCAATATCATCTATATTT 
NRS76           TTTAATCTTAACCGTGTAATTGCTCATTAAAGATTATCCCAATCAATATCATCTATATTT 
                ************************************************************ 
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Figure 2.18, continued 
 
COL_MBSa2       GTTGTACCACTATTATCTTTTTCTCTTTCTCTTACTTTGTCCATTGTACCAGTAGATTCA 
C6              GTTGTACCACTATTATCTTTTTCTCTTTCTCTTACTTTGTCCATTGTACCAGTAGATTCA 
C18             GTTGTACCACTATTATCTTTTTCTCTTTCTCTTACTTTGTCCATTGTACCAGTAGATTCA 
G5              GTTGTACCACTATTATCTTTTTCTCTTTCTCTTACTTTGTCCATTGTACCAGTAGATTCA 
G10             GTTGTACCACTATTATCTTTTTCTCTTTCTCTTACTTTGTCCATTGTACCAGTAGATTCA 
G14             GTTGTACCACTATTATCTTTTTCTCTTTCTCTTACTTTGTCCATTGTACCAGTAGATTCA 
S14             GTTGTACCACTATTATCTTTTTCTCTTTCTCTTACTTTGTCCATTGTACCAGTAGATTCA 
S15             GTTGTACCACTATTATCTTTTTCTCTTTCTCTTACTTTGTCCATTGTACCAGTAGATTCA 
NRS28           GTTGTACCACTATTATCTTTTTCTCTTTCTCTTACTTTGTCCATTGTACCAGTAGATTCA 
NRS76           GTTGTACCACTATTATCTTTTTCTCTTTCTCTTACTTTGTCCATTGTACCAGTAGATTCA 
                ************************************************************ 
 
COL_MBSa2       AGATATATTGTCTCTTGTATACTTTTCCAATCTTCTAAACCTATAATCACAGCATTATTT 
C6              AGATATATTGTCTCTTGTATACTTTTCCAATCTTCTAAACCTATAATCACAGCATTATTT 
C18             AGATATATTGTCTCTTGTATACTTTTCCAATCTTCTAAACCTATAATCACAGCATTATTT 
G5              AGATATATTGTCTCTTGTATACTTTTCCAATCTTCTAAACCTATAATCACAGCATTATTT 
G10             AGATATATTGTCTCTTGTATACTTTTCCAATCTTCTAAACCTATAATCACAGCATTATTT 
G14             AGATATATTGTCTCTTGTATACTTTTCCAATCTTCTAAACCTATAATCACAGCATTATTT 
S14             AGATATATTGTCTCTTGTATACTTTTCCAATCTTCTAAACCTATAATCACAGCATTATTT 
S15             AGATATATTGTCTCTTGTATACTTTTCCAATCTTCTAAACCTATAATCACAGCATTATTT 
NRS28           AGATATATTGTCTCTTGTATACTTTTCCAATCTTCTAAACCTATAATCACAGCATTATTT 
NRS76           AGATATATTGTCTCTTGTATACTTTTCCAATCTTCTAAACCTATAATCACAGCATTATTT 
                ************************************************************ 
 
COL_MBSa2       TCGGCATTATTGCCACTAATATAAATTGGTTCGTGATTATTATTAACATTTTTTAGTAAT 
C6              TCGGCATTATTGCCACTAATATAAATTGGTTCGTGATTATTATTAACATTTTTTAGTAAT 
C18             TCGGCATTATTGCCACTAATATAAATTGGTTCGTGATTATTATTAACATTTTTTAGTAAT 
G5              TCGGCATTATTGCCACTAATATAAATTGGTTCGTGATTATTATTAACATTTTTTAGTAAT 
G10             TCGGCATTATTGCCACTAATATAAATTGGTTCGTGATTATTATTAACATTTTTTAGTAAT 
G14             TCGGCATTATTGCCACTAATATAAATTGGTTCGTGATTATTATTAACATTTTTTAGTAAT 
S14             TCGGCATTATTGCCACTAATATAAATTGGTTCGTGATTATTATTAAC------------- 
S15             TCGGCATTATTGCCACTAATATAAATTGGTTCGTGATTATTATTAACATTTTTTAGTAAT 
NRS28           TCGGCATTATTGCCACTAATATAAATTGGTTCGTGATTATTATTAACATTTTTTAGTAAT 
NRS76           TCGGCATTATTGCCACTAATATAAATTGGTTCGTGATTATTATTAACATTTTTTAGTAAT 
                ***********************************************              
 
COL_MBSa2       TGATAAAAATCTTTTCTCGCTTCTGTAGGGCTAGTGATAATCAT      Sequence Identity 
C6              TGATAAAAATCTTTTCTCGCTTCTGTAGGGC-------------      100% 
C18             TGATAAAAATCTTTTCTCGCTTCTGTAGGGC-------------      100% 
G5              TGATAAAAATCTTTTCTCGCTTCTGTAGGGC-------------      100% 
G10             TGATAAAAATCTTTTCTCGCTTCTGTAGGGC-------------      100% 
G14             TGATAAAAATCTTTTCTCGCTTCTGTAGGGC-------------      99% 
S14             --------------------------------------------      100% 
S15             TGATAAAAATCTTTTCTCGCTTCTGTAGGGC-------------      100% 
NRS28           TGATAAAAATCTTTTCTCGCTTCTGTAGGGC-------------      99% 
NRS76           TGATAAAAATCTTTTCTCGCTTCTGTAGGGC-------------      99% 
                *******************************                
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CHAPTER 3 
DEVELOPMENT OF A FLUOROMETRIC ASSAY FOR STAPHYLOCOCCUS AUREUS 
YOEBSA1 RIBONUCLEASE ACTIVITY 
 
Sections from Chapter 3 have been reproduced from “Characterization of the In Vitro 
Ribonuclease Activity of the YoeBSa1 Toxin from Staphylococcus aureus” Larson, A. S., and 
Hergenrother, P. J. J Biol Chem 2013. Manuscript in preparation. 
 
3.1  INTRODUCTION 
 The discovery of promising drug leads in target-based high-throughput screening 
campaigns is determined largely by three factors: the nature of the target, the design of the assay 
employed in the screen, and the compounds present in the screening collection. The first two 
factors are tightly correlated, as a thorough understanding of target biochemistry is a prerequisite 
for the development of an appropriate and informative assay amenable to high-throughput 
screening. However, even a robust and sensitive assay will fail to yield hits if none are present in 
the screening collection. 
Successful exploitation of bacterial toxin-antitoxin (TA) systems as novel antibacterial 
targets necessitates a thorough characterization of toxin biochemistry to guide the development 
of an activity assay that can be utilized in a high-throughput format. The toxin YoeBEc from the 
Escherichia coli YefM-YoeBEc TA system exhibits ribosome-independent ribonuclease (RNase) 
activity in vitro (1) as well as ribosome-dependent RNase activity in vitro and in E. coli (2). The 
homologous YoeBSa1 and YoeBSa2 toxins from Staphylococcus aureus were found to induce 
growth arrest and to exhibit RNase activity similar to that of YoeBEc upon overexpression in E. 
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coli, suggesting that they are ribosome-dependent RNases with the same mechanism of action as 
YoeBEc (3). However, an in vitro assay for ribosome-dependent RNase activity would require 
reconstitution of a complex system involving actively translating ribosomes and would therefore 
be challenging to use in a high-throughput fashion to screen for activators of YoeBSa1 and 
YoeBSa2. In contrast, ribosome-independent RNase activity can be conveniently monitored 
through cleavage of a fluorogenic oligonucleotide substrate by the RNase of interest (4). Based 
on their homology to YoeBEc, it was hypothesized that YoeBSa1 and YoeBSa2 also possess 
ribosome-independent RNase activity, which could facilitate the design and implementation of 
fluorometric assays to screen for activators of these toxins. 
This thesis chapter describes the characterization of the ribosome-independent RNase 
activity of YoeBSa1 and the development of a fluorometric assay for YoeBSa1 RNase activity. A 
significant challenge when studying toxic proteins is the difficulty associated with their 
expression and purification in E. coli. A novel solution to this problem was devised by 
incorporating a non-canonical amino acid, a photocaged tyrosine derivative, to replace a tyrosine 
that is critical for the activity and toxicity of YoeBSa1. Using protein produced through this 
method, the substrate specificity of YoeBSa1 was unveiled, enabling the creation of a fluorogenic 
substrate that can be used to monitor YoeBSa1 activity. 
 
3.2  RESULTS 
3.2.1  Attempts to Express and Purify YoeBSa1 
Evaluation of the possibility that YoeBSa1 possesses ribosome-independent RNase 
activity requires the expression and purification of full-length, functional YoeBSa1. However, 
YoeBSa1 inhibits translation initiation and induces growth arrest in E. coli (3), effectively 
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inhibiting its own overexpression. A variety of strategies were explored in attempts to obtain 
pure, functional YoeBSa1. 
Denaturing Purification—The most common method employed to obtain a functional TA 
system toxin for in vitro characterization involves co-expression of the antitoxin with the toxin, 
purification of the resulting TA complex, isolation of the toxin by denaturation of the complex, 
and subsequent refolding. The yefM-yoeBSa1 operon was cloned into pET-28a and expressed in 
E. coli. The resulting YefM-YoeBSa1 complex was purified and denatured by extensive dialysis 
in either 8 M urea or 6 M guanidine hydrochloride. However, YoeBSa1 could not be completely 
purified from residual YefMSa1 under these conditions, and efforts to refold the impure toxin led 
to substantial precipitation, indicating that pure, functional YoeBSa1 could not be obtained 
through this method. 
Selective Proteolysis of YefMSa1—An alternative to denaturing purification of the toxin 
from the TA complex is to use a commercially available protease to selectively degrade the 
labile antitoxin from the TA complex, leaving the toxin unscathed (5). The YefM-YoeBSa1 
complex was expressed and purified as described above and subjected to digestion with trypsin. 
Analysis of the digest products by SDS-PAGE suggested that YoeBSa1 remained intact while 
YefMSa1 was rapidly and selectively degraded. However, the YoeBSa1 protein obtained from 
trypsin digestion of YefM-YoeBSa1 did not bind to YefMSa1 in pulldown experiments. Native 
PAGE of the digestion timecourse suggested that a fragment of YefMSa1 remained bound to 
YoeBSa1, prohibiting complex formation and indicating that this approach could not be used to 
obtain pure YoeBSa1. 
Fusion to GST—The yoeBSa1 gene was then cloned at the C-terminus of glutathione S-
transferase (GST) in hopes that a larger fusion partner would reduce the toxicity of YoeBSa1 by 
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preventing its ability to bind to the ribosome. However, all sequenced clones contained 
frameshift mutations introducing premature stop codons in the yoeBSa1 gene. Two rounds of site-
directed mutagenesis were carried out to correct these mutations. Additional premature stop 
codons or inactivating mutations were introduced in each round, suggesting that low levels of 
full-length GST-YoeBSa1, produced by leaky expression from the T7 promoter even in the 
absence of T7 RNA polymerase, retained the ability to bind to the ribosome, inhibit translation, 
induce growth arrest, and prevent colony formation. Only mutant clones encoding premature 
stop codons were not toxic. These results hinted that the C-terminal region of YoeBSa1 is 
necessary for activity and toxicity. As the C-terminal residues H83 and Y84 of YoeBEc are 
required for both in vitro RNase activity and toxicity in E. coli (1), the inability to clone the full-
length yoeBSa1 gene at the C-terminus of GST suggested that the analogous H87 and Y88 in 
YoeBSa1 have similar roles. 
Expressed Protein Ligation—YoeBSa1 contains a single cysteine (C84) four residues from 
the C-terminus and is therefore an excellent candidate for expressed protein ligation (EPL) 
between YoeBSa1Δ84-88 and the pentapeptide CKYHY (YoeBSa1 residues 84-88). Moreover, 
truncation prior to C84 would remove H87 and Y88 and thereby potentially reduce YoeBSa1 
toxicity, allowing overexpression in E. coli. The yoeBSa1Δ84-88 gene was therefore cloned at the 
N-terminus of the Mth RIR1 or Sce VMA intein, followed by a chitin-binding domain (CBD). 
The fusion proteins, which expressed in inclusion bodies, were purified under denaturing 
conditions, refolded, and incubated with the thiol reagent 2-mercaptoethanesulfonic acid to 
produce the activated C-terminal thioester required for EPL. However, intein-mediated cleavage 
did not occur even after extensive incubation periods, indicating that this approach could not be 
used to obtain full-length, functional YoeBSa1. 
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3.2.2  Expression and Purification of YoeBSa1-Y88TAG and YoeBSa1-Y88F 
Taken together, the above results indicated that the C-terminal portion of YoeBSa1 is essential for 
toxicity. Mutation of the C-terminal Y84 of YoeBEc to phenylalanine or alanine was previously found to 
diminish both in vitro RNase activity and toxicity in E. coli (1), suggesting that similar mutations to the 
homologous C-terminal Y88 of YoeBSa1 might sufficiently reduce toxicity to allow expression in E. coli. 
To investigate the contribution of Y88 to the toxicity of YoeBSa1, the TAT codon for Y88 in 
YoeBSa1 was changed to TAG for the amber stop codon (Y88TAG) or to TTT for phenylalanine 
(Y88F) (Figure 3.1). The genes encoding these mutants were cloned into pET-28a and expressed 
in E. coli, and the resulting proteins were purified and analyzed by ESI mass spectrometry (ESI-
MS) (Figure 3.2). Each protein had the expected molecular weight of the corresponding full-
length mutant (Figure 3.2A: YoeBSa1-Y88TAG, expected molecular weight: 12,307 Da, 
Figure 3.1 Nucleotide sequence of pET-28a-yoeBSa1 constructs. A (His)6-tag is encoded 
upstream of the yoeBSa1 gene. IPTG induces expression of (His)6YoeBSa1. The “XXX” codon 
highlighted in red at the C-terminus was mutated from the wild-type TAT codon for tyrosine 
to TAG for the amber stop codon and to TTT for phenylalanine to allow expression of 
YoeBSa1-Y88F and YoeBSa1-Y88TAG, respectively. 
    RBS        Start             His6-tag 
....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
         10        20        30        40        50        60        70 
AAGAAGGAGATATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGC 
Native YoeBSa1 start 
....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
         80        90        100       110       120       130       140 
AGCCATATGGCTAGGTTAAATATTACGTTTTCGCCTCAAGCCTTTGAAGATTATAAGTATTTTCAGCAGA 
 
....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
         150       160       170       180       190       200       210 
ACGATAAAAAAATGGTGAAGAAAATTAATGAGTTACTTAAAAGTATTGACAGAAATGGTGCATTGGAAGG 
 
....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
         220       230       240       250       260       270       280 
 
TATAGGTAAGCCTGAAAAGTTAAAATCGAATCTGACTGGGTATTATAGTAGACGTATCAATCACGAACAT 
                                                        YoeBSa1 stop 
....|....|....|....|....|....|....|....|....|....|....|....|... 
         290       300       310       320       330       340  
AGATTGGTTTATACAGTAGATGACAATCATATAAAAATAGCATCATGTAAATACCATXXXTAA 
                                                             Y (Wild Type) TAT
                                                             F TTT
                                                             Stop TAG
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observed: 12,303 Da; Figure 3.2B: YoeBSa1-Y88F, expected molecular weight: 12,454 Da, 
observed: 12,450 Da). These results indicated that Y88 contributes to YoeBSa1 toxicity in E. coli 
and suggested that a non-permanent modification of the structure of Y88 might sufficiently 
alleviate the toxicity of YoeBSa1 to allow expression in E. coli. 
 
3.2.3  Expression and Purification of YoeBSa1-Y88ONBY 
In vivo unnatural amino acid (UAA) mutagenesis enables the incorporation of a non-
canonical amino acid site-specifically into a protein via the use of an aminoacyl-tRNA 
synthetase (aaRS)/tRNA pair that is orthogonal to the host organism’s translational machinery 
(6-8). The photocaged UAA o-nitrobenzyl tyrosine (ONBY) has been incorporated into a 
number of proteins in which a tyrosine is critical for enzymatic activity (9-13). Mutation of 
tyrosine to ONBY “cages” the enzyme by inhibiting catalysis, substrate binding, or both. 
Irradiation with UV light between 300 and 365 nm releases o-nitrosobenzaldehyde (14), 
unveiling the free tyrosine and activating the enzyme for catalysis (Figure 3.3). As Y88 
Figure 3.2 ESI-MS and SDS-PAGE analysis of YoeBSa1-Y88TAG and YoeBSa1-Y88F. A, 
YoeBSa1-Y88TAG (expected molecular weight: 12,307 Da; observed: 12,303 Da). B, 
YoeBSa1-Y88F (expected molecular weight: 12,454 Da; observed: 12,450 Da). SDS-PAGE 
lanes, left to right: Kaleidoscope protein standards (Bio-Rad), expression culture lysate 
immediately prior to induction with IPTG, and expression culture four hours after induction. 
Asterisks indicate full-length protein. 
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contributes to the toxicity and, presumably, the activity of YoeBSa1, it was hypothesized that 
substitution of Y88 with ONBY would allow expression of an inactive, non-toxic YoeBSa1 
variant that could be activated by UV light following expression and purification. 
The pEVOL plasmids for UAA mutagenesis encode an optimized amber (TAG) stop 
codon suppressor tRNA and two copies of an evolved UAA-specific Methanocaldococcus 
jannaschii aaRS, one under the control of a constitutive glnS’ promoter and the other under the 
control of an arabinose-inducible araBAD promoter, which allows the expression level of the 
aaRS to be finely tuned (Figure 3.4) (15). As Y88 is the last residue in YoeBSa1, it would be 
challenging to purify ONBY-containing YoeBSa1 from prematurely truncated YoeBSa1. A variety 
Figure 3.3 Photocontrol of enzyme activity using ONBY. Incorporation of ONBY inhibits 
enzyme activity. Exposure to 300-365 nm UV light causes loss of o-nitrosobenzaldehyde to 
reveal the catalytic tyrosine and activate the enzyme. 
Figure 3.4 pEVOL plasmids encode two copies of an aaRS (purple arrows) under the control 
of constitutive (glnS’) and inducible (araBAD) promoters (red arrows), one copy of an 
optimized TAG suppressor tRNA (navy arrow) under the control of a constitutive promoter 
(proK, red arrow), the p15A origin of replication (p15A, yellow), chloramphenicol 
acetyltransferase (Cm
R
, blue), and the araC repressor (green). Adapted from ref. 15 with 
permission from Elsevier. 
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of expression conditions were therefore screened by ESI-MS for maximal incorporation of 
ONBY into YoeBSa1. Maximum incorporation was achieved when 1 mM ONBY was present in 
the culture medium from the beginning of the expression, when aaRS expression was induced in 
early logarithmic growth phase, and when YoeBSa1 expression was induced in late logarithmic or 
early stationary phase and allowed to proceed overnight at 37°C (Figure 3.5A; YoeBSa1-
Figure 3.5 ESI-MS analysis of YoeBSa1-Y88ONBY decaging. A, YoeBSa1-Y88ONBY prior 
to exposure to UV light (expected molecular weight: 12,606 Da; observed: 12,573 Da). B-F, 
YoeBSa1-Y88ONBY exposed to UV light for 1, 2, 3, 4, or 5 min (expected molecular weight: 
12,470 Da; observed: 12,468-12,469 Da). 
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Y88ONBY expected molecular weight: 12,606 Da, observed: 12,573 Da). The discrepancy 
between the observed and predicted masses is attributed to reduction of the ONBY nitro group to 
an amino group during ESI-MS in protic solvents (16), resulting in a loss of 30 Da that 
corresponds to the observed mass shift. Importantly, very little truncated YoeBSa1-Y88TAG is 
present (expected molecular weight: 12,307 Da, observed: 12,305 Da). UV light-induced loss of 
o-nitrosobenzaldehyde was followed by ESI-MS (Figure 3.5B-F; YoeBSa1 expected molecular 
weight: 12,470). The extent of decaging increased as UV exposure was increased up to 3 
minutes, after which no further decaging was observed (Figure 3.5D-F). 
 
3.2.4  Evaluation of the Ribosome-Independent Ribonuclease Activity of YoeBSa1 
The ribosome-independent RNase activity of YoeBSa1 was assessed toward yefM-yoeBSa1 
RNA in vitro. Decaging of YoeBSa1-Y88ONBY resulted in UV-light dependent degradation of 
the RNA (Figure 3.6A). In agreement with ESI-MS data showing that the extent of decaging did 
not increase following three minutes of UV exposure (Figure 3.5D-F), the RNase activity of 
YoeBSa1-Y88ONBY did not increase with UV exposure greater than three minutes (Figure 
3.6A). YoeBSa1 activity was inhibited by the addition of an equimolar amount of YefMSa1 
(Figure 3.6B), demonstrating that the observed RNase activity was due specifically to YoeBSa1 
and not to RNase contamination. This result also suggests that YefMSa1 inhibits YoeBSa1 at a 
one-to-one ratio, which is identical to the ratio of YefMEc to YoeBEc required to inhibit YoeBEc 
ribosome-independent RNase activity in a similar in vitro assay (1). Comparison of the activity 
of decaged YoeBSa1 with that of YoeBSa1 mutants and YefMSa1 reveals that YoeBSa1-Y88ONBY 
retains weak in vitro RNase activity, while YoeBSa1-Y88F degrades RNA very slowly, and no 
detectable RNase activity is observed for YoeBSa1-Y88TAG or YefMSa1 (Figure 3.6C). 
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Figure 3.6 RNase activity of YoeBSa1 mutants. A, RNase activity of YoeBSa1-Y88ONBY 
exposed to UV light for 0, 5, 10, 20, 30, 60, 120, 180, 240, or 300 s and incubated with yefM-
yoeBSa1 RNA for 2 h. Buffer controls were incubated with yefM-yoeBSa1 RNA for 0 or 2 h. B, 
Inhibition of YoeBSa1 by YefMSa1. YoeBSa1-Y88ONBY was exposed to UV light for 3 min. 
YefMSa1 and YoeBSa1 were mixed and incubated at 37°C for 30 min to allow complex 
formation prior to incubation with yefM-yoeBSa1 RNA at 37°C for 1 h. “–” designates 0 pmol 
protein, “+” designates 10 pmol protein, and right triangles designate increasing protein from 
10-30 pmol. C, RNase activity of YoeBSa1, YoeBSa1-Y88ONBY, YoeBSa1-Y88F, YoeBSa1-
Y88TAG, and YefMSa1. 10 pmol protein was incubated with yefM-yoeBSa1 RNA for 0, 1, 2, 4, 
8, 12, 16, or 20 h. Lane M: Low-Range ssRNA Ladder (1000, 500, 300, 150, 80, and 50 nt; 
NEB). Lane B: buffer + RNA at 20 h. Top panel only: YoeBSa1-Y88ONBY was exposed to 
UV light for 3 min. 
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3.2.5  Determination of YoeBSa1 Sequence Specificity 
The Pentaprobes are a set of twelve plasmids that together encode every possible 
combination of 5 nucleotides in sequences of ~100 nucleotides per plasmid (17). The 
Pentaprobes have been used to determine the sequence specificity of RNases with recognition 
sequences of five or fewer nucleotides (Figure 3.7). Cleavage of each Pentaprobe by the RNase 
of interest is assessed by PAGE. Once cleaved Pentaprobes are identified, deconvolution occurs 
via MALDI-MS analysis of cleavage of small oligonucleotides (5). 
The RNase activity of YoeBSa1 toward each of the twelve Pentaprobe RNA transcripts 
was assessed by denaturing PAGE. YoeBSa1 was least active toward Pentaprobe 1 and most 
active toward Pentaprobes 4, 7, and 10 (Figure 3.8A, other Pentaprobes not shown). Cleavage of 
Pentaprobe 7 was the most dramatic, with rapid and significant degradation of the full-length 
parent band and appearance of a number of smaller discrete product bands, indicating that 
YoeBSa1 cleaves this Pentaprobe at multiple sites. The sequence of Pentaprobe 7 is rich in purine 
residues (Figure 3.8B), suggesting that the sequence specificity of YoeBSa1 might be similar to 
that of YoeBEc, which cleaves RNA after purine residues with a preference for adenosine (1). 
Figure 3.7 Schematic illustrating determination of RNase sequence specificity using 
Pentaprobes and MALDI-MS. Overlapping oligonucleotides designed from the cleaved 
Pentaprobe(s) enable identification of the consensus cleavage sequence using MALDI-MS. 
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To identify the specific sequence recognized and cleaved by YoeBSa1 within Pentaprobe 
7, cleavage of three overlapping oligonucleotides spanning Pentaprobe 7 (Figure 3.8C) was 
assessed by MALDI-MS. YoeBSa1 cleaved each oligonucleotide selectively after guanosine 
residues, leaving a 3’-cyclic phosphate on each 5’ RNA product. This suggests that YoeBSa1 is a 
guanosine-specific RNase in vitro and furthermore that the mechanism of YoeBSa1 RNA 
cleavage involves activation of the 2’-OH for nucleophilic attack of the 3’ phosphodiester bond. 
Fragments corresponding to both the 5’ and 3’ products were observed for five of the nine 
Figure 3.8 Determination of YoeBSa1 sequence specificity using Pentaprobes. A, RNase 
activity of YoeBSa1 toward Pentaprobes 1, 4, 7, and 10. Lane M: Low-Range ssRNA Ladder 
(NEB). Buffer lanes: RNA was incubated in buffer alone for 0 or 2 h. –UV lanes: YoeBSa1-
Y88ONBY was incubated with RNA for 2 h. +UV lanes: YoeBSa1-Y88ONBY was exposed to 
UV light for 2 min and incubated with RNA for 0.5, 1, 1.5, or 2 h. B, Sequence of Pentaprobe 
7. C, Sequences of PP7-1, PP7-2, and PP7-3. YoeBSa1 cleavage sites identified by MALDI-
MS are indicated with arrows. D, YoeBSa1 consensus cleavage sequence. 
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guanosines in PP7-1, six of thirteen in PP7-2, and one of four in PP7-3. Most of the non-cleaved 
guanosines were near the termini of the oligonucleotides, which reduces the likelihood of 
observing cleavage at these sites by MALDI due to the 2 kDa lower mass limit of the detector 
and a reduction in MALDI sensitivity with increasing oligonucleotide length. YoeBSa1 may also 
require a minimum number of residues 5’ or 3’ from the cleavage site in order to bind and cleave 
RNA and thus may skip guanosines near the termini of an oligonucleotide. 
In the consensus sequence cleaved by YoeBSa1, adenosine residues precede and follow 
the guanosine at the cleavage site (Figure 3.8D). This may be an artifact of oligonucleotide 
design and selection, as most of the guanosines in Pentaprobe 7 are preceded by one or more 
adenosines. However, it is also possible that YoeBSa1 prefers to cleave after guanosines in the 
midst of purine-rich sequences. The fact that YoeBSa1 cleaved PP7-3 at only one of the three 
internal guanosines suggests that the ability of YoeBSa1 to cleave free mRNA may be inhibited 
by secondary structure, as PP7-3 had more predicted secondary structure than PP7-1 and PP7-2, 
which may have limited the ability of YoeBSa1 to access other potential cleavage sites in PP7-3. 
 
3.2.6  Design of a Fluorogenic Substrate for YoeBSa1 
With the objective of developing a YoeBSa1 substrate that could be used to assess the 
activation of this RNase in a high-throughput setting, a fluorogenic oligonucleotide substrate was 
designed based on the data presented in Figure 3.8. An analogous design was previously used 
for the creation of a substrate for the ribosome-independent RNase MazF (4). One of the 
sequences from PP7 that was cleaved by YoeBSa1 was converted into a 15-mer chimeric 
oligonucleotide with eight internal RNA residues surrounded by DNA nucleotides for stability 
(Figure 3.9). Based on the sequence specificity of YoeBSa1 identified using the Pentaprobes, 
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cleavage was predicted to occur after the central guanosine residue. A 6-carboxyfluorescein 
fluorophore (495 nm excitation, 520 nm emission) and an Iowa Black FQ quencher (530 nm 
absorbance maximum) were appended to the 5’ and 3’ ends, respectively, of the oligonucleotide. 
In the intact substrate, proximity enables the quencher to absorb fluorescence emitted by the 
fluorophore. Cleavage of the substrate increases the distance between the fluorophore and the 
quencher, producing an increase in fluorescence that can be monitored spectrophotometrically. 
The ability of YoeBSa1 to cleave this substrate was assessed by HPLC. The retention 
times of the products from YoeBSa1 activity overlapped with those of independently synthesized 
standards (Figure 3.10A), suggesting that cleavage occurred primarily at guanosine, as 
predicted. MALDI-MS analysis of fractions collected from the elution peaks confirmed that the 
majority of cleavage events occurred at guanosine, although minor products from cleavage at the 
surrounding adenosine residues were also observed (Figure 3.10B-D). These results corroborate 
the guanosine-specificity of YoeBSa1 ribosome-independent RNase activity. 
Figure 3.9 Fluorogenic substrate design. Cleavage of the fluorogenic substrate by YoeBSa1 
releases the fluorophore from the quencher, producing a measurable increase in fluorescence 
that can be used to monitor YoeBSa1 activity. Sequences of the intact substrate and expected 
products resulting from cleavage at guanosine are shown. “r” designates RNA nucleotides. 
Figure 3.10 (p. 95) HPLC and MALDI-MS analysis of YoeBSa1 activity toward fluorogenic 
substrate. A, HPLC traces of products of YoeBSa1 activity. Black: 30 μM intact substrate. 
Green: 30 μM 5’ cleavage product. Cyan: 30 μM 3’ cleavage product. Blue: 30 μM substrate 
cleaved by 20 μM YoeBSa1 after 5 h at 25°C. Peaks in blue trace are labeled with molecular 
weights from MALDI analysis. B-D, MALDI analysis of YoeBSa1 specificity toward 
fluorogenic substrate. Peak fractions were collected from blue HPLC trace in A, concentrated, 
and submitted for MALDI-MS at the University of Illinois Mass Spectrometry Laboratory. B, 
MALDI spectrum of the first elution peak (expected molecular weight: 3115.0 Da; observed: 
3115.3 Da). C, MALDI spectrum of the early portion of the second elution peak (expected 
molecular weight: 2602.8 Da; observed: 2602.9 Da). D, MALDI spectrum of the later portion 
of the second elution peak (expected molecular weight: 2602.8 Da; observed: 2604.3 Da). 
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Figure 3.10, continued 
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3.2.7  Kinetic Analysis of the Ribosome-Independent Ribonuclease Activity of YoeBSa1  
The kinetics of YoeBSa1 RNase activity toward the fluorogenic substrate were assessed in 
384-well plate format. YoeBSa1 (5 μM) was incubated with a range of concentrations of the 
fluorogenic substrate (0.5-20 μM) to produce a set of progress curves (representative data from 
one replicate of one experiment shown in Figure 3.11A). For each experiment, a calibration 
curve was constructed by mixing the two chimeric products resulting from YoeBSa1 cleavage at a 
1:1 molar ratio in the presence of YoeBSa1 (5 μM). The relationship between fluorescence and 
concentration of the cleavage products was linear up to 1.5 μM (45 pmol; Figure 3.11B). This 
calibration curve was used to convert relative fluorescence units (RFU) at 530 nm to pmol of 
cleaved substrate. The resulting rates are plotted in Figure 3.11C.   
Figure 3.11 Kinetic analysis of YoeBSa1 activity. A, Representative set of progress curves 
from one experiment. B, Representative calibration plot from one experiment. C, Initial 
slopes of progress curves (filled circles) with Hill fit (solid curve). Error bars represent 
standard deviation (n = 3 separately purified batches of YoeBSa1, each assayed in technical 
triplicate on two different days; plotted data are the average of the average for each batch). 
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The shape of the plotted data is sigmoidal rather than hyperbolic, which suggests that 
YoeBSa1 does not follow Michaelis-Menten kinetics and that its activity may be cooperative. 
However, YoeBSa1 (5 μM) was present at a concentration similar to that of the fluorogenic 
substrate (0.5-20 μM) in each reaction. The application of Michaelis-Menten conditions requires 
the substrate to be present in significant excess over the enzyme such that the concentration of 
substrate is not substantially reduced by formation of the enzyme-substrate complex (18). In 
contrast, the conditions used in this assay are characteristic of mutual depletion systems, in 
which formation of the enzyme-substrate complex results in significant reductions in the 
concentrations of both enzyme and substrate (19). Furthermore, when the concentration of 
enzyme, ET, is equal to or greater than the Km, enzymes that follow Michaelis-Menten kinetics 
appear to have cooperative activity. The apparent cooperativity increases as ET increases relative 
to the Km (20), resulting in an increase in the substrate concentration at which half-maximal 
velocity is observed, (ST)0.5, that is given by equation (1): 
 (  )    
  
 
    (1) 
Equation (1) allows Km to be calculated from a plot of reaction velocities versus substrate 
concentration for enzymes operating under mutual depletion conditions (19,20). 
The Hill equation (2) is used to determine the kinetic parameters of enzymes that exhibit 
cooperative activity: 
   
      
 
  
    
 (2) 
where Vmax is the maximum reaction velocity, KH is the substrate concentration at which half-
maximal activity is observed, and h is the Hill coefficient. h > 1, h = 1, and h < 1 indicate 
positive, no, and negative cooperativity, respectively (21). Equation (2) was used to fit the 
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reaction velocity data in Figure 3.11C. Reaction velocities were significantly lower with 15 and 
20 μM substrate, which suggests that substrate inhibition may occur at these concentrations. 
Thus equation (2) was used to fit the reaction velocity data for substrate concentrations between 
0.5 and 10 μM, giving Vmax = 1.05 ± 0.03 pmol/min, KH = 4.9 ± 0.2 μM, and h = 2.10 ± 0.09. 
Substituting KH = (ST)0.5 in  equation (1) gives Km = 2.4 ± 0.2 μM. 
 
3.3  DISCUSSION 
One of the most significant obstacles to characterizing the activities and determining the 
structures of toxic proteins is the difficulty of overexpression in heterologous hosts such as E. 
coli. Many TA system toxins cannot be obtained in sufficient quantities for characterization 
because their overexpression arrests growth and/or kills the cells. After the failure of multiple 
strategies to provide pure, full-length, functional YoeBSa1, the fortuitous discovery that Y88 is 
required for YoeBSa1 toxicity in E. coli led to the utilization of UAA mutagenesis to replace this 
residue with the photocaged amino acid ONBY, which reduced the toxicity of YoeBSa1 to a 
sufficient degree to allow overexpression in E. coli. 
To our knowledge, this is the first reported use of in vivo UAA mutagenesis to facilitate 
the isolation and characterization of a toxin from a TA system. Incorporation of ONBY has also 
been used to overexpress a toxic zinc-finger nuclease in an inactive, non-toxic form in E. coli 
(13), suggesting that incorporation of a photocaged version of a critical catalytic residue via 
UAA mutagenesis may provide a general strategy for the expression and characterization of 
toxic enzymes, provided that an appropriate aaRS/tRNA pair is available. For example, Y87 in 
YoeBSa2 is homologous to Y88 in YoeBSa1 and appears to be important for YoeBSa2 toxicity in E. 
coli. Consequently, incorporation of ONBY into YoeBSa2 using UAA mutagenesis may allow 
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YoeBSa2 expression in E. coli for in vitro characterization as well. Furthermore, aaRS/tRNA pairs 
have also been developed for photocaged cysteine, serine, and lysine (8). Photocaged versions of 
aspartate, glutamate, glycine, alanine, and histidine have been synthesized (22-24), but 
corresponding aaRS/tRNA pairs do not yet exist. A list of residues identified by mutagenesis and 
structural data to be responsible for the activity and/or toxicity of a number of TA system toxins 
is provided in Table 3.1 at the end of this chapter. Notably, each characterized toxin possesses 
one or more residues corresponding to an accessible photocaged amino acid. Introduction of 
aaRS/tRNA pairs specific for photocaged aspartate and histidine could allow for the general 
application of the photocaging strategy to express these proteins and study their activities and 
cellular roles in vitro and in vivo. 
The ability to express and purify caged YoeBSa1 facilitated the in vitro characterization of 
YoeBSa1 RNase activity. Using a combination of gel- and mass spectrometry-based assays, 
YoeBSa1 was found to cleave free mRNA sequence-specifically after guanosine residues. This 
specificity was used to design a chimeric fluorogenic substrate to analyze the kinetics of YoeBSa1 
activity. However, in order to observe YoeBSa1 activity toward this substrate, it was necessary for 
the concentrations of YoeBSa1 and the fluorogenic substrate to be roughly equal (5 μM and 0.5-
20 μM, respectively). As a result, the Michaelis-Menten equation could not be used to fit the 
reaction velocity data. Furthermore, the sigmoidal shape of the kinetic data suggested that 
YoeBSa1 activity was influenced by cooperativity. As few monomeric enzymes with single 
substrate binding sites are truly cooperative (21), the observed cooperativity may be an artifact of 
the high concentration of YoeBSa1 used in these experiments (20). 
Nonetheless, it is possible that the ribosome-independent RNase activity of YoeBSa1 is 
actually characterized by positive cooperativity and that a conformational change is required for 
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ribosome-independent RNA cleavage. An alternative possibility is that YoeBSa1 undergoes 
oligomerization, as YoeBEc was previously crystallized as a dimer and was observed to dimerize 
at concentrations of 1.7-16 μM (1). In a dimer of YoeBSa1, substrate binding to one monomer 
could induce a conformational change that would be propagated to the other monomer, 
facilitating RNA binding and cleavage by both and resulting in the positive cooperativity 
observed in the kinetic data. Further investigation into the potential relationship between 
conformational changes or dimerization and YoeBSa1 RNase activity will be necessary to test 
these hypotheses. However, if a conformational change or dimerization event enables or 
enhances the ribosome-independent RNase activity of YoeBSa1, the active conformation or dimer 
will likely have reduced affinity for YefMSa1. As a result, it may be possible to discover a 
YoeBSa1 activator that facilitates or stabilizes formation of the active conformation or dimer to 
enhance the activity of YoeBSa1 while simultaneously inhibiting the binding of YefMSa1. 
The relatively high Km (2.4 ± 0.2 μM) and low Vmax (1.05 ± 0.03 pmol/min) observed for 
YoeBSa1 activity toward of free RNA suggest that ribosome-independent RNase activity is 
unlikely to make a significant contribution to the activity of YoeBSa1 in cells. This is consistent 
with prior evidence for ribosome-dependent RNase activity only upon overexpression of 
YoeBSa1 in E. coli (3). One potential drawback of using the fluorometric assay to screen for 
YoeBSa1 activators is that molecules that directly activate YoeBSa1 by preventing or disrupting its 
interaction with YefMSa1 could also inhibit its ability to bind to the ribosome and cleave 
ribosome-associated mRNA. However, if these compounds stabilize an active conformation or 
oligomeric state of YoeBSa1, as proposed above, it may not be necessary for YoeBSa1 to bind to 
the ribosome or cleave ribosome-associated mRNA, as activation of its guanosine-specific RNA 
cleavage would result in global mRNA degradation, inhibition of translation, and growth arrest. 
101 
 
3.4  CONCLUSIONS 
The toxins YoeBSa1 and YoeBSa2 exhibit ribosome-dependent RNase activity and induce 
growth arrest upon overexpression in E. coli, suggesting that artificial activation of YoeBSa1 or 
YoeBSa2 could provide a novel antibacterial strategy against S. aureus. To facilitate the design 
and implementation of an assay that could be used in a high-throughput format to identify and 
characterize activators of YoeBSa1, the possibility of ribosome-independent RNase activity for 
YoeBSa1 was explored. Efforts to obtain pure, functional of YoeBSa1 using traditional methods 
were unsuccessful but led to the discovery that the C-terminal Y88 was critical for in vitro 
activity and toxicity in E. coli. This residue was mutated to ONBY using unnatural amino acid 
mutagenesis, which allowed expression of YoeBSa1-Y88ONBY in E. coli in the absence of 
YefMSa1. Photocaged YoeBSa1-Y88ONBY displayed UV light-dependent RNase activity toward 
free mRNA in vitro. In contrast to YoeBEc, which cleaves RNA at both adenosine and guanosine 
with a preference for adenosine, YoeBSa1 was found to cleave mRNA specifically at guanosine. 
Using this information, a fluorometric assay was developed and used to determine the kinetic 
parameters for ribosome-independent RNA cleavage by YoeBSa1. In the future, this assay will 
facilitate high-throughput screening of chemical and peptide libraries to identify molecules 
capable of activating YoeBSa1 via prevention of YefM-YoeBSa1 complex formation or direct 
disruption of the complex. 
 
3.5  MATERIALS AND METHODS 
Bacterial Strains—MRSA isolate S4 and NRS3 were from a previously published 
collection (25). E. coli DH5α and NiCo21(DE3) (New England Biolabs (NEB)) were used for 
cloning and protein expression, respectively. 
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Primers—All primers used for cloning and site-directed mutagenesis were synthesized by 
Integrated DNA Technologies (IDT) and are listed in Table 3.2. 
Construction of Plasmids—The yoeBSa1 ORF was PCR-amplified from the total DNA of 
MRSA S4 (25) with primers YoeBSa1-NdeI-F and YoeBSa1-Y88F-HindIII-R or YoeBSa1-
Y88TAG-HindIII-R and cloned into the corresponding sites of pET-28a (Novagen) to create 
pET-28a-yoeBSa1-Y88F and pET-28a-yoeBSa1-Y88TAG, respectively. The yefM-yoeBSa1 ORF was 
PCR-amplified from the total DNA of MRSA S4 (25) with primers YefMSa1-NdeI-F and 
YoeBSa1-HindIII-R and cloned into the corresponding sites of pET-28a. Because a single non-
silent point mutation was found in the sequence for YefMSa1, Quikchange site-directed 
mutagenesis was performed with primers YefMSa1-QC-F and YefMSa1-QC-R to create pET-28a-
yefM-yoeBSa1. Site-directed mutagenesis was carried out with the Quikchange site-directed 
mutagenesis kit (Stratagene) according to the manufacturer’s instructions with the modification 
that E. coli DH5α was used as the host strain. The yefMSa1 ORF was PCR-amplified from the 
total DNA of MRSA NRS3 (25) with primers YefMSa1-NdeI-F and YefMSa1-XhoI-R and cloned 
into the corresponding sites of pET-28a to create pET-28a-yefMSa1. All clones were confirmed by 
sequencing. Antibiotics were used at concentrations of 50 μg/ml kanamycin (pET-28a), 35 μg/ml 
chloramphenicol (pEVOL-ONBY), and 100 μg/ml ampicillin (Pentaprobes). 
ONBY Synthesis—o-Nitrobenzyl tyrosine (ONBY) was synthesized according to a 
previously published method (26) with some modifications. 2.0 g (11 mmol) L-tyrosine was 
stirred with 1.9 g (7.6 mmol) CuSO4·5H2O in 20 ml 1 M NaOH at 60°C for 20 min. The mixture 
was cooled to room temperature, quenched with hydrochloric acid, filtered, and washed with 
water. The resulting solid was stirred with 1.5 g (11 mmol) K2CO3 and 1.8 g (8.3 mmol) o-
nitrobenzyl bromide in 60 ml 75% aqueous DMF at room temperature in the dark for three days. 
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The resulting solid was filtered; washed with 75% aqueous DMF, water, 75% aqueous acetone, 
and ice-cold acetone; stirred in 100 ml 1 M HCl for 2 h; filtered; stirred in 100 ml 1 M HCl for 1 
h; filtered; and washed with water and acetone. Yield: 1.8 g (5.7 mmol, 69%). 
Purification of YoeBSa1-Y88F and YoeBSa1-Y88TAG—pET-28a-yoeBSa1-Y88F or pET-
28a-yoeBSa1-Y88TAG was introduced into E. coli NiCo21(DE3). Overnight cultures were grown 
in LB/kanamycin with single colonies from freshly streaked plates, diluted 1:100 in 
LB/kanamycin, and grown at 37°C. When the A600 of the culture reached 0.4 to 0.6, protein 
expression was induced with 1 mM IPTG at 37°C for 4 h. Cultures were harvested by 
centrifugation at 6000 × g for 5 min at 4°C in a Sorvall SLA-3000 rotor. Cell pellets were frozen 
at -20°C, thawed on ice for 30 min, and resuspended in 10 ml cold lysis buffer (20 mM Tris, 500 
mM NaCl, 60 mM imidazole, pH 7.9). Cells were lysed by sonication on ice at 40% amplitude 
for 5 min with a 1 s pulse. The lysate was cleared by centrifugation at 35,000 × g for 30 min at 
4°C in a Sorvall SS-35 rotor. The supernatant was batch-loaded onto 1 ml 1:1 Ni-NTA agarose 
(Qiagen) at 4°C for 30 min with inversion. The resin was washed with 20 ml cold lysis buffer 
and eluted with 10 ml cold elution buffer A (50 mM Tris, 500 mM NaCl, 500 mM imidazole, 1 
mM TCEP, 10% glycerol, pH 7.9). The eluted fraction was concentrated to ~0.5 ml using an 
Ultra-15 Centrifugal Filter Unit with Ultracel-3 membrane (Amicon), 0.2 μm filtered, and further 
purified on a HiLoad 16/60 Superdex 75 PG column (GE Healthcare) using FPLC buffer A (50 
mM Tris, 200 mM NaCl, 1 mM TCEP, 10% glycerol, pH 7.9). Fractions containing pure protein 
were pooled and concentrated to ~0.5-1 ml. Purity was assessed by SDS-PAGE using 4-20% 
TGX Mini-PROTEAN gels (Bio-Rad). Concentration was determined by densitometry and by 
BCA assay (Pierce) performed according to the manufacturer’s instructions with the 
modification that lysozyme was used to prepare standard solutions. 
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Purification of YoeBSa1-Y88ONBY—pET-28a-yoeBSa1-Y88TAG and pEVOL-ONBY were 
introduced into E. coli NiCo21(DE3). Overnight cultures were grown in 
LB/kanamycin/chloramphenicol with single colonies from a freshly streaked plate and diluted 
1:100 in LB/kanamycin/chloramphenicol. 100 mM ONBY dissolved in 1 M NaOH was added to 
a final concentration of 1 mM, and the culture was grown at 37°C in the dark. When the A600 of 
the culture reached 0.5 to 0.6, arabinose was added to a final concentration of 0.2% to induce 
expression of ONBY-aaRS. When the A600 of the culture reached 1.0 to 1.2, IPTG was added to 
a final concentration of 1 mM to induce expression of YoeBSa1-Y88ONBY. Expression was 
allowed to proceed at 37°C for 15 h. Cultures were harvested and YoeBSa1-Y88ONBY was 
purified in the dark as described above for YoeBSa1-Y88F and YoeBSa1-Y88TAG. 
Purification of YefMSa1—pET-28a-yefMSa1 was introduced into E. coli NiCo21(DE3), and 
protein expression and purification were performed as described for YoeBSa1-Y88F and YoeBSa1-
Y88TAG, except that YefMSa1 was eluted with 10 ml cold elution buffer B (20 mM Tris, 500 
mM NaCl, 500 mM imidazole, pH 7.9). Gel filtration was performed twice using FPLC buffer B 
(20 mM Tris, 500 mM NaCl, pH 7.9) in order to remove RNase contamination. Fractions 
corresponding to the second major peak from the first gel filtration step were pooled, 
concentrated, and re-subjected to gel filtration. Fractions corresponding to the second major peak 
from the second gel filtration step were pooled, concentrated, and used in experiments. Purity 
was assessed by SDS-PAGE using 4-20% TGX Mini-PROTEAN gels (Bio-Rad). Concentration 
was determined by BCA assay (Pierce) performed according to the manufacturer’s instructions 
using bovine serum albumin standards. 
ESI-MS—5 μg YefMSa1, YoeBSa1-Y88F, YoeBSa1-Y88TAG, and YoeBSa1-Y88ONBY 
was precipitated according to a previously published method (27). YoeBSa1-Y88ONBY was 
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exposed to 312 nm UV light on a UV transilluminator (Fisher Biotech) for 0-600 s prior to 
precipitation. Precipitated, air-dried protein was analyzed by ESI-MS at the University of Illinois 
Mass Spectrometry Laboratory. 
Agarose Gel RNase Activity Assay—pET-28a-yefM-yoeBSa1 was digested with XhoI 
(NEB) at 37°C for 3 h. The fully linearized plasmid was extracted once with 24.5:24.5:1 
phenol:chloroform:isoamyl alcohol (Sigma-Aldrich) and twice with chloroform, precipitated 
with 3 M NaOAc, pH 5.3, and 100% EtOH, and resuspended in nuclease-free water. 1 μg 
linearized plasmid was used as template for standard RNA synthesis with the T7 High Yield 
RNA Synthesis Kit (NEB) according to the manufacturer’s instructions. RNA was purified with 
reagents from the Total RNA Kit I (Omega Bio-Tek) according to the RNA Cleanup protocol 
from the RNeasy Mini Handbook (Qiagen). RNase assays were performed according to a 
modified published method (1). For light-dependence of decaging, 10 pmol YoeBSa1-Y88ONBY 
in 50 mM Tris, 5% glycerol, pH 8.0, was exposed to UV light for 0-5 min. 320 ng yefM-yoeBSa1 
RNA was then added with Human Placental RNase Inhibitor (NEB) at a final concentration of 1 
unit/μl. Reactions were incubated at 37°C for 2 h and stopped by adding 1 μg proteinase K 
(Invitrogen) and incubating at 37°C for 15 min. 11 μl RNA loading dye I (95% formamide, 18 
mM EDTA, 0.025% SDS, 0.025% bromophenol blue) was then added, and samples were 
incubated at 95°C for 5 min immediately prior to loading on 1.2% agarose, 0.5X TBE (45 mM 
Tris-borate, 1 mM EDTA, pH 8.3), 0.1 μg/ml EtBr gels for analysis. For inhibition of YoeBSa1 
by YefMSa1, YoeBSa1 (10, 20, or 30 pmol) in 50 mM Tris, 5% glycerol, pH 8.0, was exposed to 
UV light for 3 min. YefMSa1 (0, 10, 20, or 30 pmol) was then added. Following incubation at 
37°C for 30 min to allow complex formation, 320 ng yefM-yoeBSa1 RNA was added with Human 
Placental RNase Inhibitor at a final concentration of 1 unit/μl. Reactions were incubated at 37°C 
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for 1 h, stopped, and analyzed as described above. For the time course of YoeBSa1 and YefMSa1 
RNase activity, 10 pmol YoeBSa1-Y88ONBY, YoeBSa1-Y88F, or YoeBSa1-Y88TAG, or YefMSa1 
was incubated with 320 ng yefM-yoeBSa1 RNA in the presence of 1 unit/μl Human Placental 
RNase inhibitor in 50 mM Tris, 5% glycerol, pH 8.0. One set of reactions containing YoeBSa1-
Y88ONBY were exposed to UV light for 3 min prior to adding RNA. Reactions were incubated 
at 37°C for 1-20 h, stopped, and analyzed as described above. 
Polyacrylamide Gel RNase Activity Assay—Quikchange site-directed mutagenesis was 
performed with primers PP1QC1-F and PP1QC1-R to insert a G into Pentaprobe 1 and with 
primers PP1QC2-F and PP1QC2-R, PP2QC-F and PP2QC-R, PP4QC-F and PP4QC-R, PP6QC-
F and PP6QC-R, PP7QC-F and PP7QC-R, PP8QC-F and PP8QC-R, PP9QC-F and PP9QC-R, 
PP10QC-F and PP10QC-R, and PP12QC-F and PP12QC-R to introduce XbaI sites into 
Pentaprobes 1, 2, 4, 6, 7, 8, 9, 10, and 12, respectively. Site-directed mutagenesis was carried out 
with the Quikchange site-directed mutagenesis kit (Stratagene) according to the manufacturer’s 
instructions with the modification that E. coli DH5α was used as the host strain. Pentaprobe 
plasmids were digested with XbaI (NEB) at 37°C for 3 h. Fully linearized plasmids were purified 
by phenol-chloroform extraction as described above. RNA was synthesized and purified as 
described above. RNase assays were performed according to a modified published method (5). 1 
μg YoeBSa1-Y88ONBY was incubated with 1 μg Pentaprobe RNA in 50 mM Tris, pH 8.0, for 
0.5-2 h at 37°C. Reactions were quenched by adding 1 μg proteinase K and incubating at 37°C 
for 15 min. An equal volume of RNA loading dye II (95% formamide, 5 mM EDTA, 0.025% 
bromophenol blue) was then added, reactions were incubated at 95°C for 5 min to denature the 
RNA, and the products were analyzed by electrophoresis on 8% polyacrylamide TBE-urea gels 
(89 mM Tris-borate, 2 mM EDTA, 8 M urea, pH 8.3) and post-stained with EtBr. 
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MALDI RNase Activity Assay—PP7-1, PP7-2, and PP7-3 were synthesized by Genscript. 
10 μg YoeBSa1-Y88ONBY was incubated with 2 μg oligonucleotide for 1 or 2 h at 37°C. 
Reactions were quenched by adding 10 μg proteinase K (Invitrogen) and incubating at 37°C for 
30 min followed by precipitation with 5 M NH4OAc (final concentration 2 M) and 3 volumes 
100% EtOH at -80°C. Pellets were washed with ice-cold 70% EtOH, resuspended in 1 μl H2O, 
and submitted for MALDI-MS at the University of Illinois Mass Spectrometry Laboratory. 
HPLC RNase Activity Assay—The fluorogenic chimeric oligonucleotide substrate 5’-6-
FAM-AACrArArArArGrArArAAATT-IABkFQ-3’ (6-FAM, 6-carboxyfluorescein fluorophore; 
IABkFQ, Iowa Black FQ quencher) and the cleavage products 5’-6-FAM-AACrArArArArG-3’ 
and 5’-rArArAAATT-IABkFQ-3’ were synthesized by IDT. YoeBSa1 (20 μM) was incubated 
with the fluorogenic substrate (30 μM) in buffer at 25°C for 5 h. High-performance liquid 
chromatography (HPLC) was performed using an Alliance HPLC System (e2695 Separations 
Module, Waters) with detection at 260 nm (2489 UV/Visible Detector, Waters). A YMCbasic S5 
column (4.6 × 150 mm, 5 μm, Waters) was used to separate the full-length oligonucleotide from 
the cleavage products with a linear gradient from 100 mM triethylammonium acetate (TEAA), 
pH 7.0, to 50 mM TEAA/50% acetonitrile, pH 7.0, over 25 min. Peak fractions were collected, 
concentrated to 5-10 μl (Thermo Scientific Savant ISS110 Speed Vac Concentrator), and 
submitted for MALDI-MS at the University of Illinois Mass Spectrometry Laboratory. 
Fluorometric Assay—Wells of a black 384-well plate were filled with 15 μl 0.5-20 μM 
intact fluorogenic substrate or cleavage products diluted in assay buffer (200 mM sodium 
phosphate, pH 6.0, 5% glycerol) and allowed to equilibrate for 30 min at room temperature. 
YoeBSa1-Y88ONBY was diluted to 10 μM in assay buffer, exposed to UV light at 312 nm for 3 
min, and added to wells containing intact substrate and cleavage products to a final concentration 
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of 5 μM. Fluorescence was measured once every minute for 100 min using a Criterion Analyst 
AD (Molecular Devices) with 485 ± 15 nm excitation and 530 ± 15 nm emission filters and a 
505 nm cutoff dichroic mirror. The fluorophore was excited with a 1000 W continuous xenon arc 
lamp with 10 reads per well. Three separately purified batches of YoeBSa1-Y88ONBY were each 
assayed in technical triplicate on two different days. Results are the average of the average rate 
for each batch of protein. 
Construction of Calibration Plot—Fluorescence values for 1:1 molar mixtures of the 
cleavage products at 30 min after addition of YoeBSa1 were used to construct a calibration plot of 
pmol cleaved substrate versus relative fluorescence units (RFU). A separate calibration plot was 
constructed each time the fluorometric assay was performed. 
Kinetic Analysis—In some of the progress curves, an increase in fluorescence was not 
observed until ~15 min after addition of YoeBSa1. However, the increase in measured 
fluorescence was linear over the majority of the remainder of the assay. Consequently, initial 
rates were calculated from the linear portion of the progress curves between 20 and 30 min. 
Fluorescence values were corrected by subtracting measured fluorescence at 20 min from 
subsequent time points. Corrected fluorescence values were converted to pmol cleaved substrate 
using the slope from the calibration plot, and linear regression was performed using Microsoft 
Excel to obtain initial velocities. Linear velocities were plotted versus substrate concentration, 
and the resulting data points were fit with the Hill equation using Origin 8.0 software. 
 
 
 
 
109 
 
3.6  TABLES 
Table 3.1 Residues responsible for the activity and/or toxicity of various TA system toxins. 
 
Toxin Source(s) Residues Implicated in Activity and/or Toxicity 
CcdB (28,29) V. fischeri, Plasmid F Trp99, Gly100, Ile101 
Doc (30) Plasmid P1 His66, Asp70 
FitB (31) N. gonorrhoeae Asp5, Glu42, Asp104, Asp122 
HigB (32) Proteus spp. His92 
HipA (33) E. coli Ser150, Asp209, Asp332 
Kid (34) E. coli Asp75, Arg73, His17 
MazF (35) E. coli Glu24, His28 
MqsR (36) E. coli Lys56, Gln68, Tyr81, Lys96 
PemK (37) B. anthracis Glu24, His59 
PezT (38,39) S. pneumoniae Lys45, Asp66, Thr 118, Arg157, Arg170 
RelE (40) E. coli Arg61, Arg81, Tyr87 
VapC-3 (41) M. tuberculosis Asp9, Glu43, Asp99, Asp117 
VapC-5 (42) M. tuberculosis Asp26, Glu57, Asp115, Asp135 
VapC (43) S. flexneri Asp7, Glu42, Asp98 
YafQ (44) E. coli His50, His63, Asp67, Trp68, Arg83, His87, Phe91 
YoeB (1) E. coli Glu46, Arg65, His83, Tyr88 
ζ (45) S. pyogenes Lys46, Asp67 
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Table 3.2 Primers used in this study. 
 
Primer Sequence 
PP1QC1F 5’-CTT GCC TTA TCT TAC TTT TCT AGA GGG CCC TAT TC-3’ 
PP1QC1R 5’-GAA TAG GGC CCT CTA GAA AAG TAA GAT AAG GCA AG-3’  
PP1QC2F 5’-CTT GGT ACC GGA ATT CTA CGA ATT TTT CTT TTG TTT ATT TC-3’  
PP1QC2R 5’-GAA ATA AAC AAA AGA AAA ATT CGT AGA ATT CCG GTA CCA AG-3’  
PP2QCF 5’-GTT GCG CTC TAT TCT TCT AGA GGG CCC TAT TC-3’  
PP2QCR 5’-GAA TAG GGC CCT CTA GAA GAA TAG AGC GCA AC-3’  
PP4QCF 5’-GCC CTA ATC CCA CTC TAG AGG GCC CTA TTC-3’  
PP4QCR 5’-GAA TAG GGC CCT CTA GAG TGG GAT TAG GGC-3’  
PP6QCF 5’-GGT ACG GGA TCC CTC TAG AGG GCC C-3’  
PP6QCR 5’-GGG CCC TCT AGA GGG ATC CCG TAC C-3’  
PP7QCF 5’-GAA AAA TTC GTA GAA TTC CTC TAG AGG GCC CTA TTC-3’  
PP7QCR 5’-GAA TAG GGC CCT CTA GAG GAA TTC TAC GAA TTT TTC-3’  
PP8QCF 5’-GAA ACT AAA GTA AGA TTC TAG AGG GCC CTA TTC TAT AGT G-3’  
PP8QCR 5’-CAC TAT AGA ATA GGG CCC TCT AGA ATC TTA CTT TAG TTT C-3’  
PP9QCF 5’-GAC AGT AGA ATA GAG CTC TAG AGG GCC CTA TTC-3’  
PP9QCR 5’-GAA TAG GGC CCT CTA GAG CTC TAT TCT ACT GTC-3’  
PP10QCF 5’-CCA ATG GGT AGG ATT CTA GAG GGC CCT ATT C-3’  
PP10QCR 5’-GAA TAG GGC CCT CTA GAA TCC TAC CCA TTG G-3’  
PP12QCF 5’-GAC TCC AAC CTC ATC TAG AGG GCC CTA TTC-3’  
PP12QCR 5’-GAA TAG GGC CCT CTA GAT GAG GTT GGA GTC-3’  
YefMSa1 
NdeI F 
5’-GCG ATA CAT ATG ATT ATT AAA-3’ 
YefMSa1 
QC F 
5’-GAC AAA AGT AAA TGA TGA TAG TGA TAT GGT AAC TGT AAC ATC TAC 
TG-3’ 
YefMSa1 
QC R 
5’-CAG TAG ATG TTA CAG TTA CCA TAT CAC TAT CAT CAT TTA CTT TTG TC-
3’ 
YefMSa1 
XhoI R 
5’-AAA ATT CTC GAG TTA TTA TTA TTA TAC ATC TAT ATC TTT CGT TAT AGT 
TTT C-3’  
YoeBSa1 
HindIII R 
5’-AAA AAA AAG CTT AAT AAT GGT ATT TAC ATG ATG CTA T-3’ 
YoeBSa1 
NdeI F 
5’-AAA AAA CAT ATG GCT AGG TTA AAT ATT ACG T-3’ 
YoeBSa1 
Y88F 
HindIII R 
5’-AAA AAA AAG CTT AAA AAT GGT ATT TAC ATG ATG CTA T-3’ 
YoeBSa1Y
88X 
HindIII R 
5’-AAA AAA AAG CTT ACT AAT GGT ATT TAC ATG ATG C-3’ 
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